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Chapter 1
Introduction
1.1 Rectal Cancer: Epidemiological As-
pects
Colorectal cancer continues to represent a common malignancy
in the developed world. In Flanders, a total of 8,513 cases of in-
vasive colorectal cancer were diagnosed in the period 2000-2001,
with 3107 (36.5%) of these situated in the rectum. This inci-
dence is comparable with that in other Western and Northern
European countries.[1]
From archival data, it has been shown that actuarial 5 year sur-
vival of untreated rectal cancer patients was below 5%.[2] Im-
portant advances have been achieved in both preoperative and
surgical care, resulting in a postoperative mortality following
rectal cancer surgery from more than 50% in the first decades
1
of the twentieth century to the current mortality rate of less
than 2%. Overall survival in colorectal cancer patients is de-
termined by the stage of the disease (Table 1.1). Since most
patients present with stage II or III disease, approximately half
of all patients will be cured by a combination of surgery and
perioperative therapy.
Stage T N M 5YS (%)
0 Tis N0 M0
I T1,T2 N0 M0 73
IIA T3 N0 M0 59
IIB T4 N0 M0
IIIA T1,T2 N1 M0 44
IIIB T3,T4 N1 M0
IIIC Any T N2 M0
IV Any T Any N M1 8
Table 1.1: Overall survival (%) according to stage (TNM 6th edition) of
colorectal cancer patients in Flanders in the period 2001-2002. 5YS, 5 year
survival.
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1.2 Surgery for Rectal Cancer
Unlike the suprapromontorial part of the colon, the rectum is
fixed outside the peritoneal lining within the bounderies of the
bony pelvis.
Figure 1.1: Anatomical relationships of the rectum. Adapted from BG
Wolff, Ed. The ASCRS Textbook of Colon and Rectal Surgery. Springer,
New York, 2007.
The close relationship of the extraperitoneal rectum with nerves,
vessels, and other viscera constitutes a challenge for the surgi-
cal oncologist, who is expected to acquire a detailed knowledge
of the surgical anatomy of the small pelvis aimed not only at
complete removal of a rectal tumor but also at the prevention
3
of a deleterious functional outcome.[3,4]
Historically, rectal cancer surgery has been associated with a
prohibitively high local recurrence (LR) rate (up to 40%). The
realisation that most of these recurrences were the result of tech-
nical error has lead to the concept of ‘Total Mesorectal Excision’
(TME) as the standard of care in rectal cancer surgery. Al-
though few abbreviations have received as much attention as
‘TME’ in surgical oncology, the precise meaning of this term
is often unknown or misunderstood. The concept of complete
removal of the mesentery of the hindgut was given birth by Sir
Richard Heald, a surgeon from Basingstoke (United Kingdom).
The crux of the TME approach is the observation made together
with pathologist Phil Quirke that, in contrast to the tumor in
the bowel wall, cancer deposits in the mesorectum can extend
distally from the lower border of the rectal cancer.[5-9] Clin-
ical studies have confirmed the need for complete removal of
the mesorectum in low lying cancers.[10-12] Another important
principle in TME is the so called ’holy plane navigation’ with
sharp dissection around the tumor and pedicle package (Fig 1.2).
Indeed, blunt dissection with ‘coning in’ of the mesorectum en-
tails the risk of inadvertently entering the mesorectum, an event
that may lead to local disease recurrence.
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Figure 1.2: Illustration of the resection plane during TME. Adapted from
Skandalakis’ Surgical Anatomy, McGraw-Hill, Columbus, 2006
There is no doubt that the incidence of locally recurrent rectal
cancer has decreased substantially with high quality surgery.[13,14]
However, the true incidence is likely underestimated since pa-
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tients with metastatic disease often harbour an undetected local
recurrence.[15,16] Local recurrence causes substantial suffering
for patients, and even with extensive rescue surgery combined
with adjuvant therapy the probability of cure is very low.[17-19]
Recent national training initiatives in the UK, The Netherlands
and Scandinavia have convincingly shown that surgical qual-
ity control with implementation of TME improves not only LR
rate but also the sphincter preservation rate as well as long term
outcome. A similar multidisciplinary project (PROCARE)has
recently started in Belgium.
1.3 Perioperative Therapy in Rectal
Cancer
In parallel with improvements in surgical technique, adjuvant
and neoadjuvant therapy regimens have been developed in or-
der to lower LR rates following surgery. Theoretically, radio-
therapy (RT) is aimed at eradication of tumor deposits outside
the resection area. An important question is where local recur-
rences are located in the pelvis. A recent review of clinical and
cadaver studies looking at the location of rectal cancer recur-
rence indicated that the frequency of involvement of subsites in
local recurrence patients was as follows: posterior, 49%; lateral,
21%; inferior, 12%, and anterior, 17%.[20] The distance of the
tumor from the anal verge is a main determinant of the pat-
tern of lymph node spread.[21] Low lying cancers tend to drain
laterally towards internal iliac nodes, and these nodes should
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therefore be included in the clinical target volume.[22] The effi-
cacy of RT depends not only on the total dose, but also on the
fraction size and treatment duration. To achieve a high proba-
bility of eradicating subclinical disease, a biologically equivalent
dose (BED)of at least 30 Gray (Gy)is necessary.[23] Since the
growth rate of clonogens in rectal cancer is quite short (doubling
time 4-5 days), the radiotherapy dose-effect curve shifts to the
right when treatment time is prolonged.[24]
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Figure 1.3: Dose response curves obtained from clinical studies using preop-
erative radiotherapy in rectal cancer. Open circles indicate studies lacking
control groups. Circles with a grid indicate studies with historical con-
trols. Black circles indicate randomized trials. The area of the circle is
proportional to the number of patients in the combined radiotherapy and
surgery groups. Extending the overall treatment time causes a shift of
the curve towards higher doses. Adapted from Suwinski R, Taylor JMG,
Withers HR. Rapid growth of microscopic rectal cancer as a determinant of
response to preoperative radiation therapy. Int J Radiat Oncol Biol Phys
1998;42:943-951.
Preoperative RT has been shown to significantly lower LR rate
in seven of the nine randomized trials for which appropriate data
have been reported.[25-31] Postoperative RT, on the other hand,
resulted in a statistically significant reduction in LR rate in only
one of six trials.[32] The only randomized trial comparing preop-
erative with postoperative RT in rectal cancer showed a lower
LR rate with the preoperative approach, even when a higher
dose was used postoperatively.[33] Interestingly, the overall sur-
vival advantage of preoperative RT is less impressive and smaller
than what is obtained with postoperative combined chemother-
apy and radiotherapy. A significant overall survival gain was
demonstrated only in the Swedish rectal cancer trial[26] and a
small Brazilian trial.[34]
Both preclinical and clinical studies have shown that RT does
not increase the acute toxicity or anastomotic leak rate pro-
vided a careful planning is performed.[35,36] There is, however,
a concern regarding the effect of RT on functional outcome.
Anorectal function following sphincter preservation is mainly
determined by the length of remaining rectum, presence of a
reservoir (J-pouch; coloplasty) and preoperative sphincter func-
tion. Nevertheless, clinical data suggest that bowel function
is significantly worse in patients who underwent RT specifi-
cally when large fractions were used.[37,38] Postoperative sex-
ual function has been less well studied, but the available results
suggest that RT adversely affects both male and female sex-
ual function following pelvic RT combined with surgery.[39,40]
Careful preservation of the hypogastric sympatic branches and
lateral parasympatic (erecting) branches during surgery is of
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paramount importance in order to preserve sexual and bladder
function.[41,42]
The goal of combining RT with chemotherapy is to improve the
therapeutic ratio of the combined therapy.[43] This is achieved
by spatial cooperation, independence of toxicity, and enhance-
ment of tumor response. The additivity of drug-RT interac-
tions is based on an increased susceptibility of DNA to radiation
damage, inhibition of cellular repair mechanisms, cell cycle ef-
fects, elimination of hypoxic cells, and prevention of accelerated
clonogen proliferation.[44-46] The results from randomized tri-
als performed in the eighties demonstrated that postoperative
chemoradiotherapy (CRT) is superior to either postoperative
RT alone, chemotherapy (CT) alone or surgery alone.[47,48] As
a consequence, this approach was recommended by the National
Institutes of Health for all Stage II and III rectal cancers.[49]
The experience with preoperative CRT initiated in the setting
of unresectable disease, where local control and ultimate R0 re-
section were noted to be within reach in many patients.[50-52]
Extension of this approach to the setting of resectable rectal
cancer was therefore a logical step, and multiple phase II tri-
als have demonstrated a promising pathological complete re-
sponse (pCR)rate with an acceptable acute toxicity following
CRT and a 6-8 weeks waiting period.[53-57] Patients with a po-
tentially threatened circumferential resection margin (CRM) or
very low lying cancers would theoretically benefit from preop-
erative CRT. The preoperative approach has a number of ad-
vantages over postoperative CRT, including improved radiosen-
sitivity, possibility of downsizing and downstaging, avoidance
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of RT toxicity to the small bowel and the anastomosis, and
better therapy compliance. These assumptions were confirmed
by the German randomized trial comparing preoperative with
postoperative CRT using 50.4 Gy with 5-FU.[58] The preopera-
tive approach was associated with a significantly lower LR rate,
reduced toxicity, and improved sphincter preservation in a sub-
set of patients deemed to require amputation before enrolment.
Overall survival was not significantly different.
Currently, data are available from three randomized trials com-
paring preoperative RT with CRT in resectable rectal cancer:
EORTC 22921, FFCD 92-03, and a Polish trial.[59-65] In the
Polish trial, the RT dose and fractionation were different in both
study arms: short term RT (5x5 Gy) was compared with with
50.4 Gy + 5-FU. The results of these trials can be summarized
as follows: compared to preoperative RT alone, the addition of
CT enhances pathological response, lowers local recurrence rate,
and may increase sphincter preservation. Acute toxicity is, how-
ever, more pronounced while overall survival is not improved by
CRT.
1.4 The Prognostic Implications of Tu-
mor Response following Multimodal
Therapy
The observation that increasing rates of pCR are obtained with
modern CT regimens leads to the interesting concept of local
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resection or even organ preservation, analogous to the setting of
epithelial cancers.[66] The validity and safety of this approach
require critical analysis of two questions: - Does pCR translate
into a better outcome? - Can pCR reliably be predicted in
patients with a favourable clinical response?
Generally, pathological response following CRT has been shown
to be prognostically favourable [67-76] although in one retro-
spective study pCR following CRT was not related to survival.[77]
Some authors have highlighted that even with complete ster-
ilization of the bowel wall, viable tumor might persist in the
mesorectum or local lymph nodes.[78-81] The clinical signifi-
cance of these remaining viable cells is, however, unclear.
1.5 Prediction of Tumor Response to
Multimodal Therapy
Accurate prediction of a pCR during or after CRT is therefore
of major interest for further therapeutic decisions and progno-
sis. Neither clinical examination nor routine imaging (CT, MRI,
endoscopic ultrasound) are reliable in predicting pCR.[82-86]
Similarly, response prediction using a wide array of immuno-
histochemical markers (p53, p21, p16, Bax, VEGF,thymidylate
synthase) has been suggested but as yet the clinical relevance
of these markers is uncertain.[87-101] Promising results were re-
cently obtained with gene expression profiling to predict CRT
response.[102]
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1.6 Response Imaging using FDG-PET
Nuclear medicine imaging using 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) allows non-invasive functional
imaging of tumor metabolic activity and is increasingly used to
monitor therapy response in several solid cancer types.[103-105]
The response to therapy can be quantified by calculating the de-
crease in standard uptake value (SUV) or by pharmacokinetic
modelling using the Patlak model[106]. In rectal cancer, the
main interest of FDG-PET concerns the diagnosis of local re-
currence.[107] Additionally, several clinical studies have shown
that response prediction to neoadjuvant CRT using FDG-PET
is superior to EUS in terms of sensitivity and specificity.[108-
110] A recent study suggested that FDG-PET is significantly
more sensitive (100%) than CT scan (54%) and MRI (71%)
in identifying therapy responders.[111] Disadvantages of FDG-
PET and combined PET-CT include the health risks and costs
of radiation exposure and isotope handling and manufacturing,
limited spatial resolution (typically limited to 5-10 mm), lim-
ited temporal resolution with inherent motion artefacts, depen-
dence on blood glucose level, limited soft tissue resolution as-
sociated with PET-CT, false positive results with inflammatory
processes, and dependence of the technique’s sensitivity on tim-
ing of the scan following completion of CRT (metabolic flare
phenomenon).[112]
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1.7 Response Imaging using Dynamic
Contrast Enhanced Magnetic Res-
onance
1.7.1 Physiology of Contrast Enhancement in
Malignant Tumors
When the size of a growing tumor exceeds 150-200 microme-
ter, delivery of oxygen and nutients requires a process of de-
velopment of new vessels termed angiogenesis.[113,114] The tu-
mor vasculature is highly irregular and tortuous and character-
ized by a number of morphological and functional abnormali-
ties such as deficient pericyte coverage, absence of a basement
membrane, deficient intercellular junctions, and presence of cel-
lular lacunae.[115-117] Moreover, tubular structures consisting
of both tumor cells and endothelial cells have been noted to
exist in tumor tissue. As a result, increased vessel wall perme-
ability resulting from a defective barrier function is one of the
best documented properties of the neoplastic vascular bed.[118]
Leakiness of the vessel wall is important because it alters the
tumor’s interstitial tissue pressure and allows macromolecules
to enter the interstitial space.
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Figure 1.4: Scanning electron microscopic (SEM) imaging of polymer cast
of normal microvasculature (a) and tumor microvasculature (b) showing
disorganization and lack of conventional hierarchy of blood vessels. Arteri-
oles, capillaries, and venules are not identifiable as such. Reproduced with
permission from McDonald DM and Choyke PL. Imaging of angiogenesis:
from microscope to clinic. Nat Med 2003; 9: 713-725.
Unlike other diagnostic and imaging modalities, magnetic reso-
nance imaging (MRI) allows to study several aspects of tumor
vascular morphology and physiology (blood flow, oxygenation,
metabolism, pH) by virtue its superior spatio-temporal resolu-
tion and the possibility to employ an array of contrast mecha-
nisms. MRI contrast mechanisms can be broadly classified as
intrinsic (endogenous) and extrinsic (Fig 1.5). Endogenous con-
trast mechanisms such as blood oxygen level dependent (BOLD)
contrast and arterial spin labeling rely on endogenous tissue
magnetic properties including susceptibility and magnetization
transfer. Extrinsic contrast arises from changes in water proton
15
relaxation behaviour induced by an exogenously administered
paramagnetic or ferromagnetic contrast agent (CA). Addition-
ally, MR molecular imaging using targeted CA holds consider-
able promise.
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Figure 1.5: Applications of MRI in the study of tumor microvascular phys-
iology. Vascular reactivity can be mapped from changes in blood oxygena-
tion level dependent (BOLD) contrast MRI in response to vasomodulators.
Magnetization transfer or arterial spin labeling provides intrinsic perfusion
contrast, in which water in a feeding artery is magnetically tagged. Ex-
ogenous contrast materials are used in dynamic contrast-enhanced MRI
to quantify blood volume, extraction fraction, and vascular permeability.
Molecular targeting tags specific moieties on blood components, endothe-
lial cells and the extracellular matrix (ECM). Reproduced with permission
from Neeman N and Dafni H. Structural, Functional, and molecular MRI
imaging of the Microvasculature. Annu Rev Biomed Eng 2003; 5: 29-56.
Dynamic contrast enhanced magnetic resonance imaging (DCE-
MRI, also termed bolus tracking MRI) adds the dimension of
time to the anatomical detail of MRI and encompasses rapid
17
serial image acquisition following intravenous injection of a CA.
Observation of the resulting dynamic changes in signal intensity
in the tissue(s) under study allows to characterize tissue vascu-
larity, capillary permeability, and volume of the extracellular
space.
From a pharmacokinetic point of view, DCE-MRI resembles a
dynamic tracer study of a multicompartment physiological sys-
tem. A ‘compartment’ here denotes a contained homogeneous
physiological entity rather than an anatomical structure. Dur-
ing the DCE-MRI experiment, water soluble CA is injected into
the vascular compartment. During the passage of CA through
the capillary networks, bidirectional diffusional exchange will
occur to and from the interstitial tissue compartment. Since
gadolinium based CA does not generally enter the cell, the in-
terstitial compartment is often termed the extravascular extra-
cellular space (EES). The observed intensity and speed of tissue
enhancement depends on the vascular supply (‘input’) and on
the extravasation or extraction of CA as it crosses the capillary
network. The extraction rate in turn depends on properties of
the capillary lining (charge, pore diameter, thickness) and on
physicochemical properties of the CA (water solubility, molecu-
lar weight, hydrodynamic volume, charge). Leakage of CA can
be mathematically described by the Renkin and Crone model of
capillary permeability:
E = F (1− e−PSF )
Where E represents the extraction rate of CA, F the plasma
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flow, and PS the permeability surface product, i.e. the prod-
uct of capillary permeability and total exchange surface. The
importance of this formula lies in the fact that it illustrates the
dependence of CA extraction (and thus the observed MRI signal
enhancement) on capillary permeability and flow. Two limiting
situations can be described:
- high permeability (or small molecule CA): PS>>F; the term
1− e−PSF
approaches to 1 and therefore E ∼= F; in this situation extraction
is flow limited.
- low permeability (or large molecular weight CA): PS<<F; ex-
traction is permeability limited.
In conclusion: in situations with high capillary permeability (or
small CA), the observed tissue enhancement will mainly result
from microvascular flow (perfusion) whereas in situations with
low permeability (or large CA) enhancement will mainly reflect
the capillary permeability. The physiological parameter under
study will therefore depend on the choice of CA (small versus
large molecular weight agent).
1.7.2 Contrast Agents used in DCE-MRI
Most MRI contrast agents approved for clinical use have a low
molecular weight (<500 Da) and, with the exception of the
blood brain barrier, diffuse readily across any normal endothe-
lium resulting in a high extraction (50%) during first pass. DCE-
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MRI with small molecular weight agents can differentiate tissues
(benign versus malignant) based on flow and perfusion charac-
teristics. They are, however, less well suited to study and mon-
itor microvascular permeability.
The clinical importance of neovascular permeability lies in the
observations that 1. changes in permeability are a well demon-
strated early surrogate marker of angiogenesis [125] and 2. most
antitumor therapies induce a ‘normalization’ of tumor vessels,
i.e. the morphology of tumor microvessels changes into a more
benign phenotype (less tortuosity, decreased diameter, decreased
permeability).[126,127] The prototypic small molecular CA is
Gd gadopentetate (Gd-DTPA, Magnevist), a molecule (MW:
547 Da) in which the toxic free Gd(III) is chelated with di-
ethylenetriamine pentaacetic acid.
Several classes of blood pool contrast agents (BPCA) have been
developed for MR angiography and functional microvascular tu-
mor imaging, both of which require agents to remain in the
normal vascular compartment but to diffuse across hyperper-
meable neoplastic endothelium. Although this group of CA is
not strictly defined, most authors include CA with a MW range
of 5000-50.000 Da.
A first group with intermediate MW (1-60 kDa) is eliminated
by glomerular filtration and therefore denoted as ‘rapid clear-
ance’ BPCA. Examples include Gd-cascade-polymer (Gadomer-
17, Schering) and P792 (Guerbet), a macrocyclic compound
consisting of a four armed tetracarboxylic chelate. A second
class consists of large MW agents composed of Gd ions cova-
lently linked to albumin. The prototypic compound is Albumin-
(Gd-DTPA)35, with a MW of 92 kDa. Incomplete elimination
20
and potential toxicity precludes the clinical use of this agent.
Another approach has been the synthesis of agents that re-
versibly bind to plasma proteins. An example of this category
is MS-325 (Schering), a low MW Gd chelate that is 95% bound
to serum albumin at equilibrium. A fourth group of BPCA
are compounds based on superparamagnetic iron oxide parti-
cles (SPIO) usually coated with dextrans. These agents have a
MW > 100 kDa, but are rapidly cleared from the blood. A sub-
set of ultra small superparamagnetic iron oxide particles (US-
PIO) has a significantly longer half-life and holds considerable
promise both in lymphatic imaging (by uptake of the compound
in lymphatic tissue) and in tumor vascular imaging (by the com-
pound’s T1 shortening effect). Even larger BPCA such as lipo-
somal structures or nanoparticles are under active development.
1.7.3 Interpretation and Analysis of DCE-MRI
Signal Intensity over Time
Several distinct phases over time can be observed during the
DCE-MRI examination (Fig 1.6). When a bolus of paramag-
netic, low molecular weight CA passes through a capillary bed,
it is transiently confined within the vascular space. The ‘first
pass’ phase includes the arrival of contrast and lasts for a few
cardiac cycles (several seconds). Within the vascular space and
in the immediate vicinity, paramagnetic contrast media produce
magnetic field inhomogeneities that result in a decrease in the
signal intensity of surrounding tissues. In most tissues, except
the brain, testes, and retina, the contrast agent rapidly diffuzes
into the EES. The rate of CA extraction depends on several
21
Contrast Agent MW (kDa) Application
Macromolecular Agents
Albumin-(Gd-DTPA)35 92 Experimental
Gd-DTPA-Polylysine 36-480 Experimental
Dextrans 52 Experimental
ZK-159560 25.9 Experimental
Rapid Clearance Agents
Gadomer-17 17 Phase II
P792 6.47∗ Phase II
P760 5.29∗∗ Experimental
Serum Albumin Binding Molecules
Gd-BOPTA 1.058 Clinical use
MS-325 0.96 phase III
B-22956 1.06 Pase II
MP-2269 na Experimental
Iron Oxide Particles
Ferumoxtran 100 Clinical
Feruglose 100 Phase II
Ferumoxtran-10 100 Phase II
P-7228 100 Experimental
Table 1.2: Macromolecular contrast agents in preclinical and clinical use.
kDa, kilodaltons; na, not available; *molecular diameter 5.05 nm; **molec-
ular diameter 2.8 nm.
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parameters including the CA size, capillary density and perme-
ability, blood flow, and size of the extracellular space. After a
short time period, diffusion of CA from the EES into the vas-
cular compartment will occur eventually resulting in a kinetic
equilibrium. This is followed by a washout phase, during which
renal elimination of the CA from the blood results in net flux
of CA from the EES into the vascular compartment. Important
tumor physiology information can be obtained by selecting a
region of interest (ROI) around a clinically relevant tumor zone
and by generating a time intensity curve of contrast enhance-
ment in the voxels contained within the ROI. Visual inspection
of the resulting curves can assist in differentiating necrotic from
viable tumor, or in the evaluation of chemotherapy effects. The
time intensity curves can also be quantified resulting in parame-
ters such as onset time (time from CA injection to the arrival in
the tissue), initial and mean gradient (slope), maximum signal
intensity, washout gradient, and area under the signal intensity
over time curve (AUC). This semi-quantitative analysis of tissue
enhancement over time has been successfully used in character-
ization and therapy monitoring of breast and bone tumors (Fig
1.7).
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Figure 1.6: Enhancement phases observed during the dynamic MR study.
(A) Uptake phase: signal intensity rises above baseline and there is a net
leakage of contrast from the blood vessels into the interstitial space. (B)
Plateau or equilibrium phase: maximum enhancement with an equilib-
rium in the movement of contrast between the plasma and extracellular-
extravascular space. (C) Washout phase: contrast starts to leave tissue
and goes back into blood vessels. Red part of graphs refer to phase in
corresponding diagram showing movement of contrast. Reproduced with
permission from Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan
LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to
radiotherapy. Lancet Oncol 2007; 8: 63-74.
Figure 1.7: Example of DCE-MRI time-intensity curves in the evaluation
of bone tumors. The curves display the change in signal intensity over
time in three regions of interest. The arrow indicates the time point at
which the bolus arrives in the artery. The type 1 curve shows an early
and fast enhancement to a maximum signal intensity, followed by early
wash-out. This type is seen in arteries, arterio-venous malformation, giant
cell tumor, multiple myeloma, and high-grade sarcoma. A type 2 curve
shows early and rapidly progressive enhancement, and is found in many
benign and malignant musculsokeletal lesions. The type 3 curve shows slow
enhancement, indicating low vascularity or slow perfusion, as in myxoma,
inactive enchondroma, cavernous hemangioma and muscle, which is often
used as reference tissue. Reproduced with permission from Verstraete KL,
Lang P. Bone and soft tissue tumors: the role of contrast agents for MR
imaging. Eur J Radiol 2000; 34: 229-246.
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1.7.4 Pharmacokinetic Modelling of DCE-MRI
data
Semiquentitative analysis of the signal intensity over time pro-
vides valuable functional information, but does not reflect CA
concentration in the tissue of interest and is subject to the vari-
abilities of the MRI machine settings including gain and scaling
factors. Pharmacokinetic modelling of DCE-MRI data allows to
derive parameters having a physiological meaning such as mi-
crovessel permeability, blood volume, and interstitial space vol-
ume. By calculating parametric maps based on a pixel by pixel
analysis, spatial heterogeneity is greatly reduced compared to
ROI analysis techniques. In contrast to semiquantitative tech-
niques, pharmacokinetic modelling is based on CA concentra-
tion changes rather than signal intensity changes. The trans-
lation of (usually T1 weighted) signal intensity values into CA
concentrations is not trivial, and critically depends on the imag-
ing sequence details.
The most commonly used pharmacokinetic models are based
on the work of Fick and Kety, who modelled the pulmonary
uptake of inert gas as a diffusion process in the context of
tracer kinetic hemodynamic measurements.[128,129] This two
compartment approach was later applied to DCE-MRI contrast
agent kinetics in brain research (blood brain barrier perme-
ability changes in multiple sclerosis).[124,130-138] Several au-
thors have formulated similar two compartment models based
on the Kety general model, and recently Tofts et al. proposed
a standard nomenclature in order to reconcile the various de-
scribed methodologies in kinetic modelling of T1 weighted DCE-
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MRI(Fig 1.8) .[124]
Figure 1.8: Factors that influence the contrast enhancement pattern fol-
lowing bolus injection of CA. Cp=concentration of contrast in plasma;
Ct=concentration of contrast in tumour extracellular extravascular space
(EES); Ve=fractional volume of EES; Ktrans=volume transfer constant
between plasma and EES; kep=rate constant between EES and plasma.
Reproduced with permission from Zahra MA, Hollingsworth KG, Sala E,
Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of
tumour response to radiotherapy. Lancet Oncol 2007; 8: 63-74.
The general two compartment kinetic model describes the change
of tissue CA concentration per unit time as
ve
dCe
dt = K
trans(Cp(t)− Ce(t))
Where Ce denotes the tissue CA concentration, Cp the plasma
concentration, Ktrans (dimension min−1)the transfer constant,
and Ve (dimensionless)the leakage space or EES fractional vol-
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ume, i.e. the percentage of the total EES volume available as
diffusion space. This formula is derived from the basic concept
of mass conservation and states that the tissue concentration is
dependent on the concentration difference between the two com-
partments times a constant (Ktrans). Importantly, this model
requires the plasma concentration (vascular input function) to
be fitted in the model. Accurate measurement of the arterial
input function, perferably in a large vessel feeding the tumor,
is not always possible. Some authors have therefore used simu-
lated data or data based on measurements in volunteers as the
vascular input function.[137, 138]
This model assumes that intravascular contrast does not con-
tribute significantly to the tissue signal. In tumors, however,
blood volume is often high and therefore the measured signal
in a tumor voxel will be composed of both extravasated and in-
travascular contrast. Several authors have attempted to include
the effects of a significant vascular component. The solution for-
mulated by Tofts is to add a vascular component: Ct = vpCp
+ veCe. The final model can then be reformulated as
Ct(t) = vpCp(t) +Ktrans
∫ t
0
Cp(t′)e
−Ktrans(t−t′)
ve dt′
The Tofts two compartment model assumes bidirectional flux
of CA. When only the first pass of the CA bolus through the
tissue of interest is analyzed, back diffusion of CA from the EES
into the vascular bed can be assumed to be negligible. In this
special case, the general model can be simplified to
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Ct = vpCp(t) +Ktrans
∫ t
0
Cp(t′)dt′
This approach is known as the graphical Patlak plot model,
which is commonly used in modelling of data obtained with
nuclear tracer imaging (PET). When a series of data is plotted
with
Ct(t)/Cp(t)
As the Y axis and
∫ t
0
Cp(t′)dt′
/
Cp(t)
As the X axis, the slope of the resulting Patlak plot represents
Ktrans.[139-141] This model is depending on the assumption
that Ktrans is small compared to Ve and does not allow to
determine the parameter Ve. It can be attractive in situations
where the image acquisition period is limited by technical or
patient related circumstances.
In addition to to parameterization of the transfer constant, blood
volume and interstitial space, more complex models allow ad-
ditionally to derive blood flow.[142-144] It should be realized,
however, that complex models require high quality data and
careful, supervised data fitting in order to avoid spurious re-
sults.
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1.7.5 Preclinical and Clinical Response Pre-
diction using DCE-MRI
Several preclinical studies have successfully used DCE-MRI to
quantify the effects of vascular targeting therapy in tumor models.[145-
167] Clinically, DCE-MRI has provided a tool to detect early tu-
mor response to targeted therapy, CT or RT in breast, soft tissue
and bone, cervical, and colorectal cancer patients.[168-185] Of
note, MMCA are as yet not available for clinical use with the ex-
ception of iron particles (SPIO and USPIO). The main clinical
interest of these agents is nodal staging using MRI, although in
principle they could be used to study tumor blood volume and
permeability by measuring T1 effects using DCE-MRI.[186-188]
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Chapter 2
Rationale and Aims
The important issue of locally recurrent disease following rectal
cancer resection has been dealt with by improvements in surgi-
cal technique (TME) and by the introduction of perioperative
therapy regimens consisting of RT either as a single modality
or in combination with chemotherapy. The Dutch rectal cancer
trial has demonstrated that even with systematic implementa-
tion of high quality surgery, many patients will benefit from
neoadjuvant RT.[1] The aim of chapter three is to provide a
systematic literature overview of the published experience with
perioperative therapy in resectable rectal cancer. Specific issues
addressed in this chapter include RT alone versus CRT, adju-
vant versus neoadjuvant regimens, and the importance of RT
dose and fractionation. The Scandinavian trials using 5x5 Gy
of preoperative RT alone followed by immediate surgery have
demonstrated a significant reduction in local recurrence rate.[2]
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Since no waiting period after completion of RT is included, tu-
mor shrinkage or downstaging will not occur at a significant
level. In patients with a potentially compromised circumferen-
tial resection margin and/or tumor located near the sphincter
apparatus, tumor downstaging is desirable by intensification of
the RT regimen.
In chapter four, we compared two regimens of intensified pre-
operative therapy in locally advanced rectal cancer patients.
One group of patients received CRT followed by surgery after
a 6 week period, while another group was treated with hyper-
fractionated accelerated RT (HART) immediately followed by
surgery. Both groups were compared in terms of local and sys-
temic side effects, recurrence rate, and long term survival.
Assessment of the degree of response to neoadjuvant therapy
is important because it influences therapeutic decisions such as
the extent of surgery but also has been shown to influence long
term outcome.[3,4] Early detection of tumor response allows to
timely abandon or upgrade therapy in patients who fail to re-
spond. Current imaging modalities to assess therapy define re-
sponse in morphological terms, i.e. downsizing or downstaging.
Since tumor shrinkage is often a late event and tumor response
does not always correlate with changes in size, functional imag-
ing strategies have been put forward to visualize early therapy
effects. Metabolic imaging using PET or PET-CT has been
shown to allow early prediction of therapy response to preop-
erative CRT.[5] Along with the metabolic activity of neoplastic
cells, the ultrastructure and function of the tumor microvascu-
lar bed could allow early detection of therapy effects.
It has indeed been recently demonstrated that angiogenesis tar-
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geting therapies induce an early ‘normalization’ of the tumor
vascular bed.[6] The observed changes after therapy include in-
creased pericyte coverage, decreased vessel diameter and den-
sity, and decreased permeability. Recent evidence suggests that
this ‘vessel normalization’ is also observed after RT.[7] Func-
tional aspects of the tumor microvascular bed and the changes
induced by antitumor therapy can be examined by DCE-MRI
using Gd based CA.[8,9] In chapter five, we examined early
changes in the tumor microvascular bed following 5x5 Gy or RT
in a rat colorectal cancer model. Functional imaging was per-
formed with DCE-MRI using P792, a rapid clearance BPCA.
The functional imaging data were fitted in a two compartment
pharmacokinetic model and the calculated vascular parameters
compared with histology.
Response to preoperative RT is variable and largely determined
by the tumor’s radiosensitivity. One of the best studied physio-
logical parameters having an influence on radiosensitivity is tis-
sue oxygenation. Numerous clinical studies have demonstrated
a strong association between tumor hypoxia, radioresistance,
and poor therapeutic outcome.[10] Strategies to improve tumor
oxygenation during therapy have therefore been actively pur-
sued. Since the blood’s oxygen content is mainly determined
by the haemoglobin level and many cancer patients are anemic,
administration of erythropoietin (EPO) theoretically could re-
sult in improved radiosensitivity and hence a better outcome.
In clinical trials using EPO, however, the expected improved
outcome has not always been observed.[11,12] Moreover, recent
preclinical data suggest that EPO itself might influence cancer
growth and tumor radiosensitivity, a finding further corrobo-
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rated by the demonstration of the EPO receptor on many cancer
cell types.[13] Tovari et al. demonstrated that EPO administra-
tion in a xenograft model significantly increased the prolifera-
tion index of the tumor-associated endothelial cells and the size
of CD31-positive intratumoral blood vessels, whereas the peri-
cyte coverage became fragmented.[14] The effect of EPO on the
response of tumor microvessels to RT is unknown. In chapter
six, we aimed to examine the effect of recombinant human EPO
on tumor microvascular morphology and function following 5x5
Gy of RT in a rat colorectal cancer model. A similar DCE-MRI
imaging method was used together with histology and immuno-
histochemistry.
2.1 References
1. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup
WH, Wiggers T, et al. Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J Med
2001;345:638-646.
2. Gray R, Hills R, Stowe R, Clarke M, Peto R, Buyse M, et al. Ad-
juvant radiotherapy for rectal cancer: a systematic overview of 8507
patients from 22 randomised trials. Lancet 2001;358:1291-1304.
3. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Cur-
ley SA, et al. Response to preoperative chemoradiation increases the
use of sphincter-preserving surgery in patients with locally advanced
low rectal carcinoma. Cancer 2003;97:517-524.
4. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LKF,
et al. A pathologic complete response of rectal cancer to preop-
erative combined-modality therapy results in improved oncological
58
outcome compared with those who achieve no downstaging on the
basis of preoperative endorectal ultrasonography. Ann Surg Oncol
2006;13:1047-1053.
5. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone
P, et al. F-18-FDG PET is an early predictor of pathologic tumor
response to preoperative radiochemotherapy in locally advanced rec-
tal cancer. J Nucl Med 2006;47:1241-1248.
6. Jain RK. Normalization of tumor vasculature: An emerging con-
cept in antiangiogenic therapy. Science 2005;307:58-62.
7. Baeten CIM, Castermans K, Lammering G, Hillen F, Wouters
BG, Hillen HFP, et al. Effects of radiotherapy and chemotherapy on
angiogenesis and leukocyte infiltration in rectal cancer. Int J Radiat
Oncol Biol Phys 2006;66:1219-1227.
8. Krssak M, Kriz M, Stefanic M, Hilberg F. BIBF 1120, a small
molecule triple angiokinase inhibitor, affects the tumor vasculature
in human tumor xenografts on nude mice as detected by DCE-MRI.
Clin Cancer Res 2005;11:8970s.
9. Jackson EF, Esparza-Coss E, Bankson A, Coxon A, Patel V,
Kendall R, et al. The effect of AMG 706, a novel tyrosine kinase
inhibitor, on vascular permeability and blood flow as assessed by dy-
namic contrast enhanced magnetic resonance imaging (DCE-MRI) in
an in vivo preclinical tumor model. Clin Cancer Res 2005;11:9037s.
10. Evans SM, Koch CJ. Prognostic significance of tumor oxygena-
tion in humans. Cancer Lett 2003;195:1-16.
11. Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I,
Kilic E, et al. Epoetin alfa improves survival after chemoradiation
for stage III esophageal cancer: Final results of a prospective obser-
vational study. Int J Radiat Oncol Biol Phys 2006;65:459-465.
12. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher
B, et al. Erythropoietin to treat head and neck cancer patients
with anaemia undergoing radiotherapy: randomised, double-blind,
59
placebo-controlled trial. Lancet 2003;362:1255-1260.
13. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, De-
whirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-
339.
14. Tovari J, Gilly R, Raso E, Paku S, Bereczky B, Varga N, et
al. Recombinant human erythropoietin alpha targets intratumoral
blood vessels, improving chemotherapy in human xenograft models.
Cancer Res 2005;65:7186-7193.
60
Chapter 3
Preoperative Combined
Modality Therapy in the
Management of Locally
Advanced Rectal Cancer
WCeelen, P Pattyn, T Boterberg, M Peeters. Eur J Surg Oncol
2006; 32: 259-268
61
3.1 Abstract
Aims: to review the use of preoperative combined modality
therapy (CMT, chemotherapy with radiotherapy) in the man-
agement of resectable rectal cancer.
Methods: a systematic search was performed on preoperative
CMT and rectal cancer. Additional information was retrieved
from hand searching the literature and from relevant congress
proceedings. We addressed the following issues: phase II studies
of preoperative CMT, preoperative radiotherapy (RT) alone ver-
sus preoperative CMT, preoperative versus postoperative CMT,
functional outcome and pathologic downstaging after CMT, pre-
diction and importance of complete response to CMT.
Results: preoperative CMT results in an average pathologi-
cal complete response (pCR) rate of 18.5% in phase II stud-
ies. Compared with preoperative RT alone, the addition of CT
significantly improves tumour response but not overall survival
while acute toxicity increases and the effect on sphincter preser-
vation is at present unclear. Preoperative CMT has been proven
to be superior to postoperative CMT in a German multicen-
ter randomized trial. The scarce available data suggest that
the addition of CT might worsen anorectal function compared
to preoperative RT alone. Although a significant pathological
response is prognostically favourable, the clinical and imaging
tools available at present do not allow to accurately predict
pCR in clinical complete responders confirming the indication
for surgery in this subgroup.
Conclusions: preoperative CMT enhances tumour response
and could therefore have a role in patients with possibly in-
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vaded resection margins or low lying cancers, although both
acute toxicity and anorectal function are worse compared to RT
alone. The final results of ongoing randomized trials will more
accurately establish the role of preoperative CMT in resectable
rectal cancer patients.
3.2 Introduction
The last decade has seen important changes in the manage-
ment of resectable rectal cancer. Advances in both surgical
technique and adjuvant therapies have markedly reduced the
incidence of recurrent disease while offering sphincter preserva-
tion to more patients with low lying cancers. Many questions
remain, however, and the increasing complexity of rectal can-
cer therapy justifies a tailored approach guided by a multidis-
ciplinary team. The aim of this overview is to focus on new
developments and current controversies surrounding preopera-
tive rectal cancer management. More specifically, the following
topics will be addressed: neoadjuvant versus adjuvant therapy;
neoadjuvant chemotherapy versus chemoradiation (CRT), clini-
cal significance and prediction of tumour response, and the con-
cept of organ preservation.
3.3 Methods
A systematic search was performed in the English literature.
The following electronic databases were searched: Cochrane
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Central Register of Controlled Trials; ISI Web of Science (Sci-
ence Citation Index, Current Contents) from 1975 until septem-
ber 2005, and Embase.com. The search was performed us-
ing both MeSH (Medical Subject Heading) terms and free text
terms:
-MeSH: “Rectal Neoplasms”[MeSH] AND “Radiotherapy”[MeSH]
AND “Drug Therapy”[MeSH]. -Free text terms: rectal, rectum,
cancer, adenocarcinoma, neoplasm, radiotherapy, irradiation,
chemotherapy, chemoradiation, radiochemotherapy, combined
modality, multimodal. No formal meta-analysis was performed.
Additionally, published proceedings of ASTRO (American Soci-
ety for Therapeutic Radiology and Oncology) and ASCO (Amer-
ican Society of Clinical Oncology) were searched from 2000 until
2005.
3.4 Results
3.4.1 TME: a Redefined Role in the Adjuvant
Therapy Era
Due to the specific anatomy and biology of rectal cancer, surgery
alone historically has been associated with local recurrence in up
to one in four patients. Neoadjuvant RT has been shown to sig-
nificantly decrease local recurrence rates provided a biologically
equivalent dose of at least 30 Gy is administered.[1] Remark-
ably, in only one of the fourteen randomized trials (the Swedish
Rectal Cancer Trial) comparing RT followed by surgery with
surgery alone was a significant survival benefit demonstrated.[2]
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The pooled isolated local recurrence rate in the surgery alone
arm of these randomized trials (which predate modern develop-
ments in surgical technique) was 17%.
The development of sharp total mesorectal excision (TME) for
low lying cancers was essentially based on the finding that tu-
mour deposits were harboured by the mesorectum distally from
the lower edge of the bowel cancer.[3-5] Pioneered by R Heald,
the results of TME have been paralleled not only by other sin-
gle centre experiences but, importantly, by nationwide training
programs resulting in a dramatic lowering of local recurrence
rates.[6-8] The question therefore arose, whether routine appli-
cation of optimal surgery would obviate the need for neoadju-
vant RT in stage II or III rectal cancer. One important answer to
this question came from the Dutch Rectal Cancer Trial (CKVO
95-04), which randomized patients to 5x5 Gy of preoperative RT
followed by TME versus TME alone after a nationwide surgical
training programme.[9] The local recurrence rate at two years
was 2.4% in the RT-plus-surgery group and 8.2% in the surgery
only group (p<0.001), with no difference in overall survival.
The recently presented 5 year results of the Dutch TME trial
show a persistently significant difference in local recurrence rate
(5.8% versus 11.3%, p<0.001).[10]
Interestingly, subgroup analysis demonstrated that RT was ef-
fective in tumours of the middle third (5-10 cm) of the rectum,
but not in tumours of the upper (10-15 cm) or lower (0-5 cm)
third. This suggests that upper third cancers are adequately
treated with surgery alone, while the relative inefficacy of RT in
lower third cancers may be explained by a different lymphatic
spread (towards lateral lymph nodes outside the mesorectum)
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and by a higher incidence of invaded resection margins in low
lying cancers.[11,12]
3.4.2 The Rationale for CMT - Preoperative
Phase II Studies
For advanced stage and/or low lying cancers, preservation of
sphincter function is an important goal even if the quality of
life advantages of this approach are still debated.[13] In the ran-
domized trials comparing preoperative RT with surgery alone
that have used a biologically equivalent dose of at least 30 Gy,
the rate of sphincter preservation did not differ between both
groups (Table 1).
In three of these trials a significant preponderance of early stage
pathological stages was noted in the RT group. A pCR was,
however, rarely achieved. The rationale to combine chemother-
apy with RT is firmly grounded in the radiobiological principles
of spatial cooperation and enhancement of tumour response.[14]
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In rectal cancer, CRT was first applied in the adjuvant (post-
operative) setting and evaluated in two randomized trials. The
Gastrointestinal Tumor Study Group (GITSG) GI-7175 study
randomized 227 patients to four adjuvant treatment arms: (1)
no adjuvant therapy, (2) chemotherapy only (fluorouracil with
semustine), (3) RT only, and (4) CRT. Overall 5 year survival
was 59% in the CRT arm versus 43% in the no adjuvant ther-
apy arm (p=0.01) and 52% in the RT alone arm (p=NS). Inter-
estingly, local recurrence rates did not differ significantly over
the 4 treatment arms.[15,16] The North Central Cancer Treat-
ment Group (NCCTG) 794751 trial randomized 204 patients
to either adjuvant RT alone or adjuvant CRT. Both local con-
trol and overall survival were significantly better with adjuvant
CRT.[17] The results of both trials lead the National Institutes
of Health (NIH) to recommend postoperative CRT as preferred
therapy in stage II and III rectal cancer.[18] Clinical experience
with preoperative (neoadjuvant) CRT initiated in the setting of
unresectable disease, where it was shown that significant down-
staging could be achieved resulting in eventual R0 resection in
many patients.[19-21] In the setting of resectable disease, neoad-
juvant CRT has been evaluated in a large number of phase II
studies using different chemotherapy regimens (Table 2).
The mean pCR rate achieved in these studies was 18.5% (95%CI:
15.6%-21.4%) with a mean sphincter preservation rate of 58.7%
(95%CI: 51.7%-65.7%). Treatment related toxicity was usually
acceptable (grade 3 toxicity: 2.8%-28%) whereas postoperative
morbidity (including anastomotic leaks) was not different from
surgery alone series. In one phase II study a prohibitive toxicity
and adverse effects on quality of life were related to neoadjuvant
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CRT using 5-FU with leucovorin.[22] Overall, the results of these
phase II studies suggest a clear rationale for preoperative CRT
in resectable rectal cancer with a potentially endangered CRM
and/or low lying tumours amenable to downsizing.
3.4.3 Preoperative RT alone versus CRT
In the setting of unresectable disease, 4 small randomized trials
comparing preoperative RT versus CRT were performed.[23-26]
Taken together, the conflicting results and methodological flaws
of these trials do not allow to draw a conclusion regarding the
superiority of CRT over RT alone. For resectable disease, the
results of both nonrandomized and randomized trials are sum-
marized in Table 3.
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From the EORTC 22921 and the French FFCD 9203 trials, only
preliminary data are available. The addition of CT significantly
improved tumour response, although overall survival was un-
affected and treatment related toxicity worsened. Interestingly,
the increase in pathological downstaging was translated into en-
hanced sphincter preservation in only 1 of the 4 randomized
studies. This finding may be explained by the reluctance of sur-
geons to perform a low anastomosis with tissue that was cancer
invaded before initiation of CRT.
The ongoing Trans-Tasman Radiation Oncology Group (TROG)
0104 study will analyze local recurrence rate after short course
preoperative RT versus long course preoperative CRT with con-
tinuous infusion 5-FU; accrual is expected to be complete around
mid 2005. Preliminary toxicity data did not show a difference
in adverse events or perioperative mortality rate between the
treatment arms.[27]
3.4.4 Preoperative versus Postoperative CMT
The often cited advantages of the preoperative approach in-
clude enhanced activity in well oxygenated tissue, better treat-
ment compliance, reduced early and late toxicity, and enhanced
sphincter preservation by tumour downstaging and downsizing.
Three large randomized trials comparing preoperative versus
postoperative CRT were initiated.
Two American trials, Radiation Therapy Oncology Group (RTOG)
94-01 and National Surgical Adjuvant Breast and Bowel Project
(NSABP) R-03, were closed prematurely due to insufficient ac-
crual. Partial results from NSABP R-03 suggested that the pre-
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operative approach resulted in increased sphincter preservation
with marginally higher treatment related toxicity (Table 4).
The recently published German multicenter trial demonstrated
that preoperative CRT was associated with improved compli-
ance, increased local control and reduced toxicity (Table 4).
Sphincter preservation rate did not differ between both treat-
ment arms. However, significantly more sphincter saving proce-
dures were performed in a subgroup of patients with low lying
cancers judged before randomization by the surgeon to require
amputation. Both the NSABP R-03 and German trial failed,
however, to show a survival advantage associated with the pre-
operative approach.
3.4.5 Is There Still a Place for Short Term,
High Dose RT?
Although the 5x5 Gy schedule has proven its efficacy in large,
conclusive randomized trials, it has been criticized due to alleged
toxicity and the unability to achieve tumour downsizing.[28,29]
An increase in treatment related morbidity and mortality was
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observed in the early Stockholm I and II trials, in which a large
volume of the pelvis and abdomen were included in the radiation
field.[30] With appropriate small bowel shielding and treatment
planning, preoperative 5X5 Gy of RT did not worsen postoper-
ative mortality in the Swedish and Dutch rectal cancer trials.
Functional outcome data from the Scandinavian and Dutch tri-
als indicate that, compared to surgery alone, preoperative 5x5
Gy of RT comes at a price.[30-32] On the other hand, data
from the Dutch rectal cancer trial suggested that, although 5x5
Gray of RT lead to more sexual dysfunction and slower recovery
of bowel function, health related quality of life was not signif-
icantly affected by preoperative RT.[33] Moreover, short term
RT is convenient for the patient, and does not delay surgery.
The 5x5 Gy regimen is aimed at eradicating microscopic dis-
ease outside the resection field. An important limitation of the
short term regimen immediately followed by surgery is that it is
unable to achieve tumour downsizing, a phenomenon observed
when a waiting period of several weeks is allowed.[34,35] Fur-
thermore, data from the Dutch rectal cancer trial indicate that
preoperative 5x5 Gy of RT cannot compensate for positive cir-
cumferential resection margins(CRM).[36] Involvement of the
CRM can be accurately predicted by preoperative high resolu-
tion thin slice MRI.[37,38]
Taken together, these data suggest that preoperative 5x5 Gy of
RT with immediate surgery is a safe and (cost)effective regimen
provided adequate RT planning is performed. For patients in
whom the CRM is at risk or sphincter preservation is an issue,
a longer waiting period and/or a longer RT regimen should be
considered. At present, no randomized studies are available
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comparing preoperative short term with long term RT alone.
The ongoing Stockholm III trial comparing preoperative 5x5
Gy with immediate surgery, 5x5 Gy with delayed surgery, and
25x2 Gy with delayed surgery will provide further important
data. Interim results from this important trial including quality
of life data will soon be available (Dr B Cedermark, Karolinska
Institute, Sweden).
3.4.6 Prediction and Prognostic Importance
of Response to CRT
Since preoperative CRT does not improve overall survival com-
pared to preoperative RT alone or postoperative CRT, the prog-
nostic significance of pathological response to CRT is unclear.
Several authors have specifically analyzed the relationship be-
tween presence and degree of pathological response and long
term outcome parameters. The degree of pathological response
is usually expressed using a semi-quantitative scoring system
such as the tumour regression grade (TRG).[39,40] While some
studies demonstrated an improved long term survival in respon-
ders, others found long term outcome to be related not to treat-
ment response but to pretreatment clinicopathological variables
such as T stage and differentiation.[41-47] Taken together, how-
ever, these studies do suggest that a significant response to
CRT is a favourable prognostic factor. In order to avoid po-
tential toxicity in non responding patients, pretreatment pre-
diction of response could be an important tool to tailor preop-
erative therapy. A number of histological and molecular markers
such as Bax expression, p53 nuclear staining, and thymidylate
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synthase expression have been identified as predictors of patho-
logical response.[48-50] Moreover,the powerful tool of gene ex-
pression profiling using microarrays was recently shown to be
of value in discriminating responders from non responders.[51]
Finally, functional imaging techniques using dynamic contrast
enhanced magnetic resonance imaging (DCE-MRI) or nuclear
scintigraphy with specific markers have been used to combine
morphological data with tumour response prediction.[52,53]
3.4.7 Significance of Complete Clinical Response
and the Concept of Organ Preservation
Modern CRT schedules result in a pCR rate exceeding 20%, and
it is likely that this percentage will increase in the years to come
with the addition of targeted therapy. As a consequence, the
concept of organ preservation with nonoperative management
in selected patients with a clinical complete response (cCR) has
emerged. The provocative study of Habr-Gama et al. compared
operative versus nonoperative treatment for stage 0 distal rec-
tal cancer following CRT.[54] In this retrospective comparison
of cCR patients who were observed versus clinical partial re-
sponse patients who underwent surgery and found to have a
pCR, long term survival and local recurrence rates were found
to be similar. However, several drawbacks concerning nonoper-
ative management in cCR patients should be considered. First,
neither clinical examination nor endoscopy or endorectal ultra-
sound were able to accurately predict a pCR in a number of
clinical studies.[55,56]
In a recent study, the negative predictive value of functional nu-
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clear imaging with PET in the prediction of pCR was only 43%,
i.e. in 19 of 51 patients with a negative PET scan did the speci-
men contain residual cancer.[57] Second, pathology studies have
shown that the mesorectum can harbour residual cancer de-
posits in patients with a complete sterilization of the bowel wall,
indicating a differential response to CRT in these 2 anatomi-
cal entities that renders biopsies of the bowel wall insufficient
as a basis for therapy decision.[58-60] The risk of nonoperative
management was illustrated by the paper of Nakagawa et al.,
who found locally recurrent disease in 8 out of 10 cCR patients
managed expectantly.[61] Nonoperative management therefore
is only acceptable in patients refusing or unfit for surgery or in
the context of a prospective clinical trial.
3.4.8 Anorectal Function after Preoperative CRT
and Sphincter Preserving Surgery
Anorectal function is known to be disturbed by a very low col-
orectal or coloanal anastomosis, and is further compromised by
preoperative RT.[62-64] Little data are available in the literature
concerning the additional effects of CRT on anorectal function
following sphincter preservation. In a small number of phase II
studies, the functional results reported suggest that CRT does
not in itself significantly worsen functional outcome.[65,66] A
prospective evaluation of CRT effects on anorectal function us-
ing anal manometry was published by Ammann et al.,who com-
pared a CRT treated group with a group who underwent surgery
alone.[67] Patients undergoing preoperative CRT showed a sig-
nificantly decreased mean resting pressure, resting vector vol-
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ume and maximal tolerable volume one year postoperatively
while these parameters were unaffected in patients treated with
surgery alone. Interestingly, low and rectoanal anastomoses re-
sulted in better anorectal function than a high anastomosis in
CRT treated patients. Preliminary functional and quality of
life (QoL) data from the EORTC 22921 trial were recently pre-
sented.[68] This four arm trial randomized patients to preoper-
ative RT versus CRT and to adjuvant chemotherapy versus no
adjuvant CT. Compared to RT alone, preoperative CRT was
associated with a significantly worse global QoL and anorectal
function in patients who underwent sphincter saving surgery.
These preliminary data suggest that the addition of chemother-
apy signifies an increased burden to the patients in terms of
QoL and anorectal function and this should be taken into ac-
count when discussing treatment options.
3.4.9 Future Perspectives
Since the improvement in local control with preoperative CRT
has until now not been reflected in a survival advantage, one
of the areas of future improvement will be the addition of more
effective systemic therapy to eradicate microscopic systemic dis-
ease. Clinical trials using a combination of chemotherapy with
targeted therapy as a component of CRT are underway.[69]
Therapeutic decisions and prognostic assessment will increas-
ingly be based on genomic and molecular profiling of the tumour
in addition to standard imaging methods. Improvements in ra-
diation technique such as conformal and intensity modulated RT
will allow to limit toxicity by better defining the target volume
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while limiting exposure of normal tissue.[70,71]
3.4.10 Conclusion
Preoperative CMT is superior to adjuvant CMT and, compared
to preoperative RT alone, enhances tumour response while acute
toxicity increases. Preoperative CMT could have a role in pa-
tients with possibly invaded resection margins or low lying can-
cers, although in the randomized trials tumour downstaging did
not always translate into an increase in sphincter preservation.
Observation of a clinical complete response to CMT does not ob-
viate the need for surgery. Preliminary data from the EORTC
22921 randomized study suggest that the addition of chemother-
apy to preoperative RT adversely affects both overall QoL and
anorectal function. The final results of ongoing randomized tri-
als will more accurately establish the role of preoperative CMT
in resectable rectal cancer patients.
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4.1 Abstract
Background: neoadjuvant therapy is increasingly used in re-
sectable locally advanced rectal cancer. The exact role of the
addition of chemotherapy (CT) is not established. We com-
pared neoadjuvant therapy using chemoradiation (CRT) with
hyperfractionated accelerated radiotherapy (HART).
Methods: Clinical, pathological and survival data were ob-
tained from patients with resectable stage II or III rectal cancer
within 7 cm from the anal verge. A group of 50 patients was
treated with a preoperative dose of 41.6 Gy of radiotherapy (RT)
in 2 daily fractions of 1.6 Gy over 13 days immediately followed
by surgery (HART). A second group of 96 patients received
45 Gy of conventionally fractionated RT in 25 daily fractions
of 1.8 Gy combined with infusional 5-FU based chemotherapy
followed by surgery within 4-6 weeks (CRT). Both groups were
compared in terms of morbidity, pathological downstaging, local
recurrence, and survival.
Results: Both groups were comparable in terms of preopera-
tive clinicopathological variables. The mean distance from the
anal verge was 5.8 cm (HART) versus 4.9 cm (CRT). Sphincter
preservation was possible in 74% (HART) versus 83.5% (CRT)
of patients (p=0.013). The clinical anastomotic leak rate was 2%
(HART) versus 2.2% (CRT). pCR was observed in 4% (HART)
versus 18% (CRT) of the resected specimens (p=0.002). A
pelvic recurrence developed in 6% (HART) versus 4.4% (CRT)
of patients (p=0.98). Overall 5 year survival was 58% (HART)
versus 66% (CRT), p=0.19 while disease free 5 year survival was
51% (HART) versus 62% (CRT), p=0.037.
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Conclusions: Compared with preoperative HART followed by
immediate surgery, preoperative CRT followed by a 6 weeks
waiting period enhances pathological response and increases sphinc-
ter preservation rate. This could be explained by the addition of
chemotherapy or the longer interval between neoadjuvant ther-
apy and surgery. No statistically significant difference was ob-
served in local control or overall survival.
4.2 Introduction
The annual incidence of fatal cases of colorectal cancer exceeds
200.000 in the European Union alone. The mainstay of therapy
in locally advanced rectal cancer remains surgery with negative
margins, including the circumferential resection margin (CRM).
Historically, surgery for rectal cancer has been associated with
locally recurrent disease in up to one in four patients.[1]
Data from a recent systematic review suggest that preoperative
radiotherapy (RT) lowers local recurrence rates provided a bi-
ologically equivalent dose of at least 30 Gy is administered.[2]
On the other hand, attention to surgical technique with precise
sharp dissection of the mesorectal plane and total mesorectal ex-
cision (TME) in lower third cancers significantly improved local
control in a number of expert series.[3-6] The question whether
preoperative RT remains effective when optimal surgical tech-
nique is systematically implemented was convincingly answered
by the results of the Dutch Rectal Cancer Trial.[7] After a na-
tionwide surgical training program, preoperative RT further re-
duced local recurrence rate (2.4% after RT+TME versus 5.3%
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in the TME alone group, p<0.001).
For patients with bulky tumors, possibly invaded lateral resec-
tion margins or tumors close to the sphincter apparatus, several
approaches to intensify preoperative RT have been employed.
The addition of chemotherapy to preoperative RT builds on the
favorable results obtained with postoperative chemoradiation
(CRT) and preoperative CRT for irresectable disease.[8] Several
phase II trials with preoperative CRT in resectable rectal cancer
have shown a promising pathological complete response (pCR)
rate and a high rate of sphincter preservation.[9,10]
The aim of hyperfractionated regimens is to separate early and
late radiation effects aiming to improve local control while lim-
iting late tissue toxicity.[11] In head and neck cancer, a random-
ized trial by the European Organization for the Research and
Treatment of Cancer (EORTC) demonstrated a significantly
better local control after hyperfractionated RT compared to
a conventionally fractionated regimen.[12] In colorectal cancer,
cell kinetic studies using biomarkers have demonstrated rapid
proliferation of clonogens, with a small potential doubling time
(Tpot) which could cause local tumor recurrence.[13-15] More-
over, because of potential rapid regrowth of subclinical tumor
deposits during RT, limiting total treatment time is important
to achieve a high probability of local control.[16] Theoretically,
therefore, rectal tumors would benefit from hyperfractionated
accelerated radiotherapy (HART).
We retrospectively compared two neoadjuvant therapy regimens
in patients with resectable locally advanced rectal cancer. Group
1 was treated with HART immediately followed by surgery.
Group 2 received neoadjuvant 5-FU based CRT followed by
96
surgery after a 4-6 weeks interval.
4.3 Methods and Materials
4.3.1 Patient Selection
All patients with resectable rectal cancer stage cT3-4 N0 or
cT1-4 with nodal disease were offered neoadjuvant therapy. Pa-
tients with possibly resectable lung or liver metastases were also
included. From 1994 until 7/2000, all patients received preop-
erative HART. After this period, given the results from various
phase II trials in both resectable and irresectable rectal can-
cer, neoadjuvant chemoradiation was introduced. Mean follow
up time for both groups was therefore different. Since most lo-
cal recurrences following rectal cancer surgery occur within two
years postoperatively and no major changes were applied in sur-
gical technique, we considered a comparison of both protocols
appropriate when looking at downstaging and local control as
endpoints.
4.3.2 Preoperative Workup
Preoperative clinical staging included clinical assessment, liver
ultrasound or CT scan, chest X-ray or CT scan, full blood analy-
sis including CEA and colonoscopy with biopsies. Routine use of
magnetic resonance imaging before and after neoadjuvant ther-
apy was introduced in 2002 and performed in 42 patients (30%).
Endoscopic ultrasound (EUS) of the tumor was performed in
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52% of the patients.
4.3.3 Radiotherapy
All patients were treated on a 25 MV Elekta linear accelerator.
The treatment was delivered in prone position with a three-field
technique (one posterior and two opposite lateral fields) on the
pelvis. The upper border was set at the L5-S1 interspace. If an
abdominoperineal resection was to be performed, the perineum
was included in the fields. The anterior border of the lateral
fields was set just posterior of the symphysis, the posterior bor-
der included the sacrum. Adequate blocking was used to exclude
excessive amounts of small intestine. The dose was prescribed
at the isocentre. A combination of wedged and open fields was
used, depending on which resulted in the most optimal dose dis-
tribution, with a homogeneity within 5% of the prescribed dose,
according to the ICRU rules. The patients in the HART group
were treated twice daily, five days a week, with an interval of
at least 6 hours. The dose per fraction was 1.6 Gy. Twenty-six
fractions were delivered, resulting in a cumulative dose of 41.6
Gy. The patients in CRT group were treated once daily, five
days a week, with a dose of 1.8 Gy. Twenty-five fractions were
delivered, resulting in a cumulative dose of 45 Gy.
4.3.4 Chemoradiation
In 85 (93%) patients, chemotherapy consisted of bolus 5-fluorouracil
(325 mg/m2) and folinic acid (10 mg/m2) given during day 1-5
and 29-33 of RT. In 6 (7%) patients, concomitant chemother-
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apy consisted of oxaliplatin (50 mg/m2) weekly for 5 weeks
and capecitabine (825 mg/m2) BID 5 days per week during 5
weeks, according to the CORE protocol (first results presented
at ECCO 2005, Paris [17]).
4.3.5 Surgery
All patients underwent nerve sparing total mesorectal excision
(TME). The decision to perform a sphincter sparing procedure
was made peroperatively, and not before initiation of neoadju-
vant therapy. Technical details included division of the inferior
mesenteric artery and vein at 1 cm from its origin, routine mo-
bilization of the splenic flexure and washout of the rectal stump
with an iodine solution prior to completion of the anastomosis.
Creation of a temporary loop ileostomy was performed in se-
lected cases as judged necessary by the operating surgeon.
The criteria for sphincter preservation were: acceptable sphinc-
ter function and absence of direct invasion of the sphincter ap-
paratus. These criteria remained unchanged throughout the
treatment period.
4.3.6 Follow Up
During treatment, patients were seen weekly and acute toxicity
was scored according to the WHO scale. Late toxicity was eval-
uated at least 12 months after surgery. Node positive (stage III)
patients were proposed six cycles of adjuvant chemotherapy.
99
4.3.7 Statistical Analysis
Data are expressed as mean (standard error), unless indicated
otherwise. Differences between means of continuous variables
were analyzed with the 2-tailed t-test or, when a non-normal
data distribution was observed, with the Mann Whitney U test.
Differences between fractions were analyzed with the Chi squared
or Fisher’s exact test where appropriate. Actuarial survival
curves were generated with the Kaplan Meier method and com-
pared using the log rank test. Statistical significance was as-
sumed at an alpha value <0.05. All calculations were performed
with SPSS 12.0 for Windows.
4.4 Results
4.4.1 Clinicopathological Variables
As illustrated in Table 4.1, no significant differences were present
between both groups regarding demographic variables, clinical
tumor stage, or distance between tumor and the anal verge. One
third of patients in both groups had a tumor within 3 cm from
the anal verge. More than half of the patients had clinically node
positive disease, and hepatic metastases deemed resectable were
present in approximately 10% of patients in both groups.
4.4.2 Neoadjuvant therapy acute toxicity
Acute gastrointestinal, urogenital and hematological toxicity
was more pronounced in the group of patients receiving CRT,
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Site Group 1 (HART) Group 2 (CRT)
N=50 N=91
Gastrointestinal
Grade 1 14 32
Grade 2 2 8
Grade 3 - -
Renal, Bladder
Grade 1 2 10
Grade 2 - 1
Grade 3 - -
Cutaneous
Grade 1 5 12
Grade 2 2 5
Grade 3 - 1
Hematological
Grade 1 - 2
Grade 2 - 1
Grade 3 - -
Table 4.2: Comparison of WHO acute toxicity episodes. HART, hyperfrac-
tionated accelerated radiotherapy; CRT, chemoradiation.
whereas cutaneous toxicity was comparable (Table 4.2). Grade
three toxicity was seen in only one patient, who received CRT
and developed a severe skin reaction. No grade four toxicity was
observed.
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4.4.3 Details and Outcome of Surgery
Details of surgery are provided in Table 4.3. Surgery was per-
formed after a mean time interval of 3 days (HART) versus
6 weeks (CRT). Significantly more sphincter preserving proce-
dures were performed in patients who received CRT. No differ-
ence was observed in clinical anastomotic leak rate. Both early
postoperative overall morbidity and late radiation induced tox-
icity, however, were significantly more pronounced in group 1
(HART) patients. In the HART group, 8 patients (16%) de-
veloped late radiation sequelae. Five patients (10%) needed
surgery for severe late radiation induced bowel damage (ra-
diorectitis 2, radioenteritis 1, rectovaginal fistula 2). Another
three patients in the HART group developed radiorectitis but
were managed medically. The median time interval between
primary and reoperative surgery was 15 months (range 2-34).
In the CRT group, two patients (2.2%) developed radioenteritis
but did not undergo reoperation.
4.4.4 Pathology data
Pathological details and downstaging rates are illustrated in Ta-
ble 4.4. Both tumor and node downstaging were significantly
more pronounced in group 2 (CRT). The pathological complete
response rate was significantly higher in patients who received
CRT. Downsizing of the resected tumor was observed in both
groups compared to the preoperative tumor size. In the CRT
group, however, tumors were significantly smaller after neoad-
juvant therapy compared to the HART group. Mucinous differ-
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Variable Group 1 (HART) Group 2 (CRT) p
N=50 N=91
Tumor size (mm) 34.4 (2.6) 22.8 (1.2) <0.001
Mucinous diff. 9 (18) 16 (18) 0.99
pT downstaging 15 (30) 45 (51) 0.02
pN downstaging 9 (18) 35 (38) 0.012
pCR 2 (4) 16 (18) 0.002
Table 4.4: Comparison of pathological details and tumor (T) and node (N)
downstaging. pCR, pathological complete response (pT0N0). Data repre-
sent mean (standard error) unless indicated otherwise. HART, hyperfrac-
tionated accelerated radiotherapy; CRT, chemoradiation. Values between
brackets are percentages.
entiation was observed in 18% of patients in both groups.
Although the percentage of patients in both groups receiving ad-
juvant chemotherapy was similar, all patients in group 1 (HART)
received a 5-fluorouracil alone regimen whereas in group 2 (CRT),
the regimen contained oxaliplatin or irinotecan in 42% of pa-
tients.
4.4.5 Local Control and Survival
Mean follow up time was 67 months in group 1 (HART) and
28 months in group 2 (CRT) (p<0.001). No patients were lost
to follow up. Overall local recurrence rate was 6% in group
1 (HART) and 4.4% in group 2 (CRT) (p=0.98). In group 1,
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all three local recurrences were isolated. Two of these patients
had a pT4 tumor and developed a presacral recurrence, while
in the third patient a lymph node recurrence developed along
the left iliac artery. In group 2, three of the local recurrences
were seen in patients with systemic disease while isolated local
recurrence was present in only one patient who presented with
pT4 disease with bilateral ureteral obstruction. The isolated
local recurrence rate was therefore 3% in group 1 versus 1.1%
in group 2 (p=0.13). As far as distant failure is concerned, 24%
of pre-treatment clinically M0 patients developed metastases in
group 1 (HART) and 11% in group 2 (CRT), p=0.02.
Survival data are illustrated in figures 4.1 and 4.2. Overall 5-
year survival was 58% in group 1 and 66% in group 2 (p=0.19).
Disease free 5-year survival was 51% in group 1 and 62% in
group 2 (p=0.037).
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Figure 4.1: Comparison of overall survival. HART, hyperfractionated ac-
celerated radiotherapy; CRT, chemoradiation.
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Figure 4.2: Comparison of disease free survival. HART, hyperfractionated
accelerated radiotherapy; CRT, chemoradiation.
108
4.5 Discussion
A multimodal approach has become the standard of care in lo-
cally advanced resectable rectal cancer. The addition of chemother-
apy to RT is firmly grounded in the principles of enhanced tu-
mor response and spatial cooperation (local versus systemic ac-
tivity).[18] Several theoretical considerations favor preoperative
CRT over postoperative CRT, and this was clinically demon-
strated in the recent German rectal cancer trial.[19] We retro-
spectively compared neoadjuvant HART immediately followed
by surgery with neoadjuvant CRT with surgery performed after
a 6 weeks period. Several non-randomized and randomized stud-
ies have compared RT alone with CRT in the preoperative ther-
apy of rectal cancer. From the EORTC 22921 and the French
FFCD 9203 trials, only preliminary data are available. Taken
together, the results of these studies indicate that the addition of
CT significantly improves tumor response, although acute toxi-
city is usually worse. Interestingly, the increase in pathological
downstaging was translated into enhanced sphincter preserva-
tion in only 1 of the 4 randomized studies. This finding may be
explained by the reluctance of surgeons to perform a low anas-
tomosis with tissue that was cancer invaded before initiation of
CRT. Moreover, the observed increase in tumor response did
not improve disease free or overall survival. Our results con-
firm an increased tumor response with CRT, with significantly
increased downstaging of both T and N status. Probably, the
difference in downsizing and downstaging between both groups
is mainly due to the different waiting period between the com-
pletion of RT and surgery. In our experience, this was translated
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into more sphincter preserving procedures, although we cannot
exclude the influence of other variables such as refinements in
surgical technique allowing more very low anastomoses to be
performed. In keeping with others, we found that preopera-
tive RT in either schedule increases the incidence of mucinous
carcinomas.[20] The anastomotic leak rate was not affected by
neoadjuvant therapy, confirming experimental data indicating
that neither RT nor CRT affect colonic anastomotic healing pro-
vided only one limb of the anastomosis is irradiated.[21,22] The
low clinical anastomotic leak rate in the present series is partly
explained by the liberal use of a deviating ileostomy. Although
presence of an ileostomy temporarily adversely affects quality
of life,[23] it has been shown to reduce the incidence of clinical
leakage and to mitigate the consequences of a leak.[24]
On the other hand, early (30 day) postoperative overall mor-
bidity (major and minor) was significantly more pronounced in
patients treated with HART, reflected by a significantly longer
hospital stay. It is possible, however, that a less liberal use of a
diverting ileostomy in HART patients is confounding the differ-
ence in 30 day morbidity rate. The rationale for HART in rectal
cancer is based on the observation of the relatively early occur-
rence of locally recurrent disease in most patients. At the origin
of a local recurrence are rapidly proliferating clonogens with a
small potential doubling time (Tpot).[14-16] Limiting the total
treatment time by accelerating RT and reducing the delay with
surgery could therefore enhance the effect on local recurrence
after rectal cancer surgery. Clinical experience with preopera-
tive HART in rectal cancer is limited. Coucke et al. reported on
two phase I trials in 20 patients treated with postoperative 41.6
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Gy of HART and 23 patients treated with 41.6 Gy of preoper-
ative HART.[25] Acute toxicity after preoperative HART was
acceptable in this report, and small bowel toxicity was signifi-
cantly lower compared to postoperative HART. There was only
one case of late bowel toxicity in the group treated preopera-
tively. The same group recently reported a phase I study com-
bining preoperative 41.6 Gy of HART with concomitant CPT-11
in locally advanced rectal cancer.[26] Major complications after
surgery were seen in 25% of patients with a considerable anas-
tomotic leak rate of 22%.
Hyperfractionation is aimed at limiting late tissue toxicity while
achieving an identical or enhanced local control. In head and
neck cancer, a randomized trial comparing a hyperfractionated
(twice daily 1.15 Gy) with a conventional (daily 2 Gy) regimen
has shown a significant increase in local control (59% versus 40%
at 5 years) with no increase in late toxicity.[12] We could not
demonstrate the late toxicity sparing of HART and, on the con-
trary, found a significant increase in late radiation sequelae with
10% of patients needing further surgery as a direct consequence
of radiation induced bowel damage. Certainly, this conclusion
has to be interpreted with caution and may even be premature,
given the significant difference in follow-up time between both
groups. Overall and isolated local recurrence rates were low
with both treatment modalities and in keeping with recent clin-
ical literature. More specifically, no influence of limiting total
treatment time was noted on the incidence of local recurrence.
One of the important questions in low-lying rectal cancer is how
the time interval between preoperative therapy and surgery, tu-
mor downstaging and sphincter preservation rate are related.
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In the Polish randomized study comparing preoperative CRT
with 5x5 Gy of preoperative RT, the observed increase in tumor
response was not translated into enhanced sphincter preserva-
tion.[27] This was explained by the fact that the surgeon’s de-
cision to perform a sphincter saving procedure was based on
the pre-treatment tumor volume. We chose to rely on the post-
treatment clinical stage, with acceptance of a peroperative free
distal resection margin of >5 mm when confirmed by frozen sec-
tion analysis. This policy resulted in a significantly higher per-
centage of sphincter saving procedures in CRT patients (83.5%
versus 74%, p=0.013).
Survival and recurrence data are to be interpreted with cau-
tion as the mean follow up time between both groups is sig-
nificantly different. Moreover, routine preoperative MRI to de-
fine the circumferential margin was performed only in the CRT
group which could lead to stage migration. Since most patients
were followed for more than 2 years, we considered it useful
to provide the disease free and overall actuarial survival data.
Overall 5-year survival was not different between the two treat-
ment modalities. Disease free 5-year survival, however, was bet-
ter in the CRT group (62% versus 51%, p=0.037). This is ex-
plained by a significantly lower occurrence of systemic failure
after CRT (11% versus 24%, p=0.02) confirming the effective-
ness of the systemic component of this neoadjuvant regimen in
patients who may already have micrometastatic disease at pre-
sentation. However, differences in the adjuvant therapy regimen
in stage III patients could partly account for the observed dif-
ference in DFS and distant metastasis rate.
In conclusion, preoperative CRT increases tumor downsizing
112
and downstaging compared to preoperative HART. This trans-
lates into a higher sphincter preservation rate at the expense of
a moderately increased acute toxicity. Postoperative both early
and late complications are significantly more pronounced after
HART. Both regimens when combined with precise surgery re-
sult in excellent local control. Systemic relapse was more com-
mon and disease free survival worse after HART, but overall
survival was not different.
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Chapter 5
Noninvasive Monitoring of
Radiotherapy Induced
Microvascular Changes using
Dynamic Contrast Enhanced
Magnetic Resonance Imaging
(DCE-MRI) in a Colorectal
Tumor Model
W Ceelen, P Smeets, W Backes, N Van Damme, T Boterberg,
P Demetter, I Bouckenooghe, M De Visschere, M Peeters, P
Pattyn. Int J Radiat Oncol Biol Phys 2006; 64: 1188-1196
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5.1 Abstract
Purpose: Prediction of response to radiotherapy (RT) in col-
orectal cancer is highly relevant for both surgical management
and prognosis in these patients. In a rat colorectal cancer model,
we studied the use of dynamic contrast enhanced magnetic res-
onance imaging (DCE-MRI) with a new macromolecular rapid
clearance MR contrast agent (P792, gadomelitol) (i) to visualize
tumor vascular leakage as a surrogate marker for angiogenesis,
(ii) to evaluate the effects of RT on this parameter, and (iii)
to compare noninvasive imaging with invasive pO2 measure-
ment, vascular endothelial growth factor (VEGF) expression,
microvascular density (MVD), and pimonidazole hypoxia stain-
ing.
Methods and Materials: male WAG/Rij rats were injected
with 2x106 CC531 cells in the hind leg. Once the tumor reached
a diameter of 8 mm, fast DCE-MRI was performed before and
5 days after 5x5 Gy of external RT. The DCE-MRI data were
used to generate parametric tissue maps of the endothelial trans-
fer constant (Ktrans) according to the Tofts-Kermode pharma-
cokinetic two-compartment model. Separate region of interest
(ROI) analyses were performed on the entire tumor (T), periph-
eral tumor rim (P), tumor core (C), and normal muscle (M). In-
vasive fiber optic tissue pO2 histogram mapping was performed
in each tumor core and rim before and after RT using a step-
wise micromanipulator technique. Finally, MVD counts, VEGF
expression and pimonidazole hypoxia staining were performed
after RT in excised tumors and compared with a group of un-
treated tumor bearing rats.
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Results: the biophysical properties of P792 allowed excellent
discrimination between tumor and normal tissue. Mean (x1000/min)
value changes measured over all pixels in a ROI were as follows:
T: 14.6 vs 3.8 (p<0.001); P: 26.3 vs 4.5 (p<0.001); C: 5.4 vs
1.8 (p<0.001), and M: 3.3 vs 2.1 (p=0.12) before and after RT
respectively. Mean pO2 was P: 6.8 mm Hg before RT vs 7.7 mm
Hg after RT (p<0.001) and C: 3.5 mm Hg before RT vs 4.4 mm
Hg after RT (p<0.001). Mean MVD in the tumor rim was 10.4
in the RT treated group vs 16.9 in the control group (p=0.061);
MVD in the tumor core was not significantly different. VEGF
expression was significantly higher in RT treated rats, but pi-
monidazole hypoxia score was not significantly different. After
RT, no significant correlation was found between DCE-MRI pa-
rameters and histological parameters. An inverse correlation
was seen after RT between pO2 and Ktrans (r=-0.57, p=0.08)
and between pO2 and Ve (r=-0.65, p=0.04).
Conclusions: DCE-MRI with P792 allows non-invasive imag-
ing and quantification of microvascular changes in this colorectal
cancer model. Administration of short term RT significantly re-
duces neovascular leakage and enhances tissue oxygenation and
VEGF expression. After RT, DCE-MRI parameters are related
to tumor pO2, but not to MVD or VEGF expression.
5.2 Introduction
Colorectal cancer remains one of the leading causes of cancer
death in the Western world.[1] Due to the specific anatomy
and biology of low rectal cancer, surgical resection alone his-
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torically has been associated with a high incidence of locally
recurrent disease. Neoadjuvant combined modality treatment
has been shown to decrease local recurrence rates even with the
use of optimal surgical technique (total mesorectal excision).[2,3]
Potential disadvantages of neoadjuvant chemoradiation include
overtreatment of overstaged disease, treatment related toxicity
and long term effects on sphincter function.[4] There is therefore
a need for noninvasive imaging techniques that allow clinicians
to predict and monitor tumor response to neoadjuvant therapy.
Magnetic resonance imaging (MRI) recently has evolved as one
of the most promising imaging modalities in the diagnosis and
staging of rectal cancer.[5] Dynamic contrast enhanced mag-
netic resonance imaging (DCE-MRI) using paramagnetic con-
trast agent administration allows one to analyse tumor specific
enhancement patterns that are governed by physiological prop-
erties such as microvascular flow, endothelial permeability and
size of the extracellular extravascular space (EES).[6] Quantita-
tive analysis of the enhancement signal using a pharmacokinetic
model can generate estimates for parameters such as the en-
dothelial transfer coefficient Ktrans.[7] The MRI contrast agents
currently in clinical use have a low (< 1 kDa) molecular weight,
diffuse readily across the endothelial barrier of both normal and
neoplastic tissues and therefore are much less suited to char-
acterize hyperpermeable neoplastic vessels.[8] Macromolecular
weight contrast media take advantage of the selective hyper-
permeability of neoplastic vessels to macromolecules and have
been used successfully to monitor angiogenesis and the effects
of anti-angiogenesis agents in preclinical studies.[9] For macro-
molecular agents, microvascular leakage determined by Ktrans
120
is relatively flow independent and therefore estimation of leak-
age changes as a surrogate marker of angiogenesis is possible
without exact measurement of capillary flow.[10]
We studied the changes in neovascular leakage of an experimen-
tal colorectal cancer during fractionated radiotherapy (RT) us-
ing DCE-MRI with P792, a new macromolecular MRI contrast
agent (CA) currently evaluated in phase II clinical trials. Non-
invasive imaging was compared with invasive tissue pO2 mea-
surement, microvessel counts, vascular endothelial growth factor
(VEGF) expression, and pimonidazole hypoxia staining.
5.3 Methods and Materials
The experimental protocol was reviewed and approved by the
Animal Ethical Committee of the Ghent University, Belgium.
5.3.1 Animals and Tumor Model
A group of 11 male Wag/Rij rats (Harlan, Horst, The Nether-
lands) was studied longitudinally with DCE-MRI and invasive
oxygenation measurements performed both before and 5 days
after completion of RT. For histology and immunohistochem-
istry, this group was compared with 9 untreated control rats
bearing tumors of similar size.
The CC531 cell line is a 1,2-dimethylhydrazine-induced, mod-
erately differentiated and weakly immunogenic colon adenocar-
cinoma, syngeneic with WAG/Rij rats. This cell line is well
studied and has been proven to provide a tumor-host model
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similar to human colorectal carcinogenesis.[11] Cells were grown
as a stationary cell line in plastic culture flasks in RPMI 1640
medium, buffered with HEPES (20 mM) (Invitrogen Corpora-
tion, Gibco, Ghent, Belgium) additionally supplemented with
10% fetal calf serum, 4 mM L-glutamine, 50 U/ml penicillin and
50 g/ml streptomycin at 37 C in a humidified atmosphere with
5% CO2 in air. The cells were transferred at 95% confluency.
Two million cells suspended in 0.2 ml were injected subcuta-
neously in the upper hind leg. Tumors reached a size of 0.5-1
cm after a period of 4 weeks. Once tumor growth of minimally 8
mm diameter was observed, a jugular vein catheter was inserted
and tunneled to the interscapular region. In order to maintain
catheter delivery function between the first and second MRI,
continuous infusion at 0.5 ml saline per hour was administered
with a cage mounted swivel and flexible metal tether system
(Uno BV, Didam, The Netherlands) allowing the animal full
mobility. To enable histological assessment, animals were sacri-
ficed by anesthetic overdose after the last in vivo measurements.
5.3.2 Radiotherapy
Rats were not sedated and the tumor bearing hind leg was im-
mobilized using a plexiglass holder, as described previously.[12,13]
Briefly, rats were placed in a purpose-built plexiglass holder in
prone position. The hind legs were pulled through an opening in
the holder and immobilized with strings. Before each fraction,
a radiation field was simulated encompassing the tumor with a
margin of 1.5 cm. The photon irradiation was performed with a
5 MV linear accelerator (Elekta, Crawley, UK). Five fractions of
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5 Gy (total dose 25 Gy) were delivered on five consecutive days.
Since the tumors were inoculated subcutaneously, they were cov-
ered with tissue-equivalent silicone bolus of 1 cm to prevent the
build-up effect under the skin. One single direct field at a fixed
source-skin distance of 100 cm was used. The dose was calcu-
lated to the midpoint of the tumors according to their volume
in each individual animal, as obtained during simulation. DCE-
MRI and oxygenation measurements were performed before and
5 days after the completion of RT.
5.3.3 Magnetic Resonance Imaging
T1 weighted DCE-MRI was performed on a clinical Siemens
Magnetom Symphony 1.5 Tesla scanner (Siemens AG, Erlangen,
Germany). Animals were sedated with 0.2-0.4 ml of medeto-
midine (Domitor, Novartis Animal Health, Basel, Switzerland).
Imaging comprised a single axial slice that was positioned through
both upper limbs and the center of the tumor. Prior to the con-
trast series, T1 zero time maps were constructed from two spin
echo sequences with different repetition times (TR 1000 ms and
318 ms, respectively). Details of this sequence were as follows:
slice thickness 3 mm, FOV 140x88, matrix size 256x160, TE
20 ms, and flip angle 90 degrees. Dynamic imaging was per-
formed with a 4 antenna wrist coil (diameter 10 cm) using an
IR-TurboFLASH sequence. Details of the pulse sequence were
as follows: temporal resolution 1.1s, FOV 140x88, matrix size
256x160, slice thickness 5 mm, TE 4.08 ms, TI 560 ms, and
flip angle: 12 degrees. A bolus injection of 0.3-0.4 ml of P792
was manually injected as fast as possible (approximately 1ml/s)
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through the central venous line after the fourth scan. A total of
500 images were obtained for a total scan time of 550 seconds.
5.3.4 Analysis of MR Images
Postprocessing was performed using the research mode of a com-
mercially available software tool (MIStar, Apollo Medical Imag-
ing, Melbourne, Australia).
The maximum cross sectional area (in cm2) of each tumor was
recorded before and after RT.
Both a qualitative description of the tissue enhancement curve
and a 2 compartment pharmacokinetic approach according to
Tofts and Kermode were implemented.[7] In each tumor, re-
gions of interest (ROI) were drawn encompassing the following
regions: the entire tumor (1), the angiogenic tumor rim de-
fined as the outer 2-3 voxel wide circumference (2), the central
necrotic area (3) and muscle tissue in the contralateral non ir-
radiated hind leg (4).
In each region, the area under the enhancement curve (AUC)
was calculated until 550 seconds after contrast arrival.
Pharmacokinetic modeling was based on a 2 compartment model
consisting of a vascular space and an EES fraction which is en-
tered by the CA leaking through the microvascular wall. De-
rived from a first order differential equation describing contrast
agent flux driven by Fick’s law of diffusion, the concentration
of CA in the tissue (Ct in mM) is described by the following
equation:
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Ct = Ktrans
∫ t
0
Cp(t′)e
−Ktrans
ve
(t−t′)dt′
where Ktrans (min-1) denotes the endothelial transfer rate, Ve
the fraction of the interstitial space (dimensionless) entered by
the CA and Cp the plasma concentration (in mM). In each tu-
mor both before and after RT, the pixel with the most represen-
tative arterial input function (AIF) was manually selected from
the femoral artery of the tumor bearing leg or the opposite leg
to provide Cp. Mean tumor tissue and arterial T1 zero (be-
fore contrast injection) values were calculated from the T1 zero
maps. These data together with the selected AIF were used
as the input for a curve fitting routine resulting in paramet-
ric maps of Ktrans and Ve. The influence of inflow effects on
leakage measurements was minimized by using a deconvolution
method in the model to separate the inflow component from the
tissue concentration Ct.[7]
Quantitative values for all pixels in the 4 different regions of
interest described above were exported to a spreadsheet for fur-
ther analysis.
5.3.5 MR Conrast Agent
Dynamic contrast studies were performed with P792 (gadomeli-
tol, Vistarem, Guerbet, Roissy, France), a new monogadolinated
rapid clearance MRI blood-pool agent which is cleared by renal
elimination. The molecular weight of the compound is 6.47 kDa,
but the mean diameter of P792 is 50.5 Angstrom and the T1
relaxivity of this agent is 29 M-1 ms-1 at 60 MHz.[14] Apparent
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hydrodynamic volume of P792 is 125 times greater than that
of Gd-DOTA (gadoterate meglumine, Dotarem) and as a result
of this high molecular volume, P792 is characterized by a lim-
ited diffusion across normal endothelium and is therefore ideally
suited to study hyperpermeable neoplastic vessels.[14] Experi-
mentally, P792 has been used to study permeability effects of
anti-angiogenesis therapy in a prostate cancer model.[15]
5.3.6 Tissue Oxygenation Measurements
Tissue oxygenation was measured in both the tumor core and
periphery with a fiberoptic probe based on fluorescence quench-
ing (OxyLite, Oxford Optronix, Oxford, UK).[16,17] A precali-
brated fiberoptic probe (diameter 280 µm) was inserted 5 mm
deep into the tumor using a Seldinger technique. This involved
insertion of a catheter with needle assembly into the tissue; the
needle was then withdrawn leaving the catheter in place through
which the probe was inserted in such a way that the probe’s tip
was exposed to the surrounding tissue. The probe was then
withdrawn in 40 steps of 100 µm each over a total distance of 4
mm using a micromanipulator (model MN151, Narishige Inter-
national Ltd, London, UK).
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Figure 5.1: Measurement of tissue pO2 by a fiberoptic probe inserted in
the tissue by a Seldinger technique. The probe is withdrawn in steps of 0.1
mm by a micromanipulator.
After each micromanipulator movement, measurements were
started as soon as a stable reading was obtained. Tissue pO2
was sampled every 2 seconds. Histograms were constructed
based on the pO2 (expressed in mm Hg) readings over the cen-
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tral one mm (core) and outer one mm (periphery) trajectory.
Both before and after RT, the hypoxic fraction (defined as per-
centage of pO2 measurements with a value of <5 mm Hg) was
determined.
5.3.7 Immunohistochemistry
Immunohistochemistry was performed on the experimental group
and on 9 untreated control rats bearing tumors of similar size.
From each tumor, half of the tissue was snap frozen in liquid
nitrogen; the other part was fixed in 4% formalin and embed-
ded in paraffin wax in the conventional manner. Microvascu-
lar density (MVD) was determined with a method modified af-
ter Weidner et al.[18] After incubating 5 micron frozen slices
with anti-CD31 antibodies (mouse anti rat CD31, clone number
TLD-3A12, Serotec, Oxford, UK), the entire tumor section was
scanned at low power (objective, 40 X) to identify ‘hot spots’,
which are the areas of highest neovascularization. Individual
microvessels were then counted under higher power (objective,
400X) to obtain a vessel count in a defined area, and the average
vessel count in 3 hot spots was taken as the MVD.
For hypoxia staining, rats were injected with 60 mg/kg iv pi-
monidazole (Hydroxyprobe Kit, Biognost, Heule, Belgium) 30
minutes before sacrifice. Paraffin embedded slides were incu-
bated with anti-pimonidazole antibodies and the resulting cyto-
plasmatic staining was expressed semiquantitatively. Membrane
staining was not observed. Immunoassaying was visualized us-
ing 3-amino-9-ethylcarbazole (Dako, Glostrup, Denmark).
VEGF expression was assessed after incubating slides with mouse
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anti human VEGF C1 monoclonal antibody (sc-7269, Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA). The
antibody used reacts with VEGF of mouse, rat and human ori-
gin. Semi-quantitative scoring of both pimonidazole staining
and VEGF expression was based on a method modified after
Coppola et al.19 with a scale ranging from 0 to 6. The scale
was based on scoring of the fraction of positive cells (0: all
cells negative; 1: <33% positive; 2: 33-66% positive; 3: >66%
positive) and the staining intensity (1: weak; 2: moderate; 3:
intense). Both scores were added to a maximum score of six.
5.3.8 Statistical Analysis
Data were analyzed and presented graphically with a statistical
software package (S-PLUS 6.1 for Windows, Insightful Corp.,
Seattle, USA). Differences in signal enhancement parameters
between 4 tissue regions were evaluated with one way anal-
ysis of variance (ANOVA). Differences in imaging parameters
and pO2 before versus after RT were assessed with the paired-
sample t-test or, when data were not normally distributed, with
the Wilcoxon signed rank test. Differences in MVD between RT
treated rats and control rats were analyzed with the unpaired t-
test, while differences in pimonidazole staining score and VEGF
expression were analyzed with the Mann Whitney U test. Cor-
relation analyses between imaging, oxygenation and histological
data were performed with the Spearman rank order test. Statis-
tical significance was inferred when p< 0.05. Data are expressed
as mean with 95% confidence interval unless stated otherwise.
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5.4 Results
5.4.1 Effect of RT on Tumor Growth
The mean cross-sectional surface area of the tumor did not
change significantly during RT: 1.5 (0.9-2.1) cm2 before RT and
1.6 (0.8-2.4) cm2 after RT (p=0.9).
5.4.2 Enhancement of Tumor versus Normal
Tissue
A similar temporal enhancement pattern was observed in all
animals (Fig 5.2 and 5.3) confirming selective MRI enhancement
of tumor tissue by P792. Before RT, the arterial input function
tended to peak at approx. 100-120 seconds. Signal enhancement
in neoplastic tissue was characterized by a short initial rapid
increase of signal intensity (SI) corresponding to the first arterial
inflow and initial rapid inwash in the tumor tissue. This 20-25
second phase was followed in tumor tissue by a slowly rising
SI increase, which was most pronounced in the tumor rim. The
tumor center displayed a similar slow uptake although the SI was
much lower. Normal muscle, however, did not enhance after the
initial fast uptake phase.
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Figure 5.2: Typical enhancement pattern in different colorectal tumor re-
gions and normal muscle before fractionated radiotherapy.
131
Figure 5.3: Typical enhancement pattern in different colorectal tumor re-
gions and normal muscle after fractionated radiotherapy.
Cumulative DCE parameter values before RT are illustrated in
Fig 5.4-5.6. Mean AUC of signal intensity was significantly dif-
ferent between entire tumor, tumor rim, tumor core, and normal
muscle (p<0.001 for all comparisons). Both pharmacokinetic
parameters were significantly different between the entire tumor,
tumor rim and tumor core (p<0.001 for all comparisons), with
the highest Ktrans observed at the tumor rim. No significant
differences in pharmacokinetic parameters were seen between
the tumor core and normal muscle (p=0.4 for both Ktrans and
Ve).
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Figure 5.4: cumulative area under the concentration time curve values
before radiotherapy in different regions of interest.
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Figure 5.5: cumulative Ktrans (endothelial transfer constant) values before
radiotherapy in different regions of interest.
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Figure 5.6: cumulative Ve (fractional interstitial space) values before ra-
diotherapy in different regions of interest.
5.4.3 Effects of RT on DCE-MRI Parameters
The effects of fractionated RT were first evaluated graphically
with parametric maps of the tumor (Fig 5.7). Both Ktrans and
Ve were significantly lower after RT in all three examined regions
of the tumor (Table 5.1). In non irradiated muscle tissue, on
the contrary, no changes were observed in Ktrans or Ve.
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Figure 5.7: Parametric map (tumor masked) of Ktrans (x1000/min) before
(above) and 5 days after (below) 5x5 Gy of radiotherapy. The arrow points
to the pixel containing the selected arterial input function.
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Parameter ROI before RT After RT p
Ktrans (min-1) Tumor 14.6 3.8 <0.0001
Rim 26.3 4.5 <0.0001
Core 5.4 1.8 <0.0001
Muscle 3.3 2.1 0.12
Ve Tumor 20.3 2.4 <0.0001
Rim 32.7 5.8 <0.0001
Core 6.3 0.5 <0.0001
Muscle 1.2 0.8 0.41
Table 5.1: Comparison of DCE-MRI parameters before and after radiother-
apy in selected regions of interest (ROI).
5.4.4 Effects of Fractionated RT on Tissue pO2
The mean number of pO2 readings per animal was 839 before
RT and 706 after RT. Mean pO2 values in both tumor regions
before and after RT are illustrated in Table 5.2 and Fig 5.8 and
5.9. Both before and after RT, the tumor core was significantly
more hypoxic compared to the tumor rim. Fractionated RT
significantly increased mean pO2 in both tumor core and rim.
The hypoxic fraction (pO2 <5 mm Hg) in the tumor core was
79.2% before and 61.9% after RT (p = 0.008). In the tumor rim,
the hypoxic fraction was 36.6% before RT and 29.9% after RT
(p = 0.3). The histogram of cumulative pO2 readings showed a
bimodal distribution in both tumor regions.
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pre RT post RT
mean (95%CI) mean (95%CI) p
Tumor rim pO2 (mm Hg) 6.8 (6.7-6.8) 7.7 (7.6-7.8) <0.001
Tumor core pO2 (mm Hg) 3.5 (3.4-3.5) 4.4 (4.3-4.4) <0.001
p <0.001 <0.001
Table 5.2: Oxygenation values in the tumor core and rim before and after
radiotherapy. CI, confidence interval.
Figure 5.8: pO2 histograms from the tumor rim before (left) and after
(right) radiotherapy.
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Figure 5.9: pO2 histograms from the tumor core before (left) and after
(right) radiotherapy.
5.4.5 Immunohistochemistry Results
Expression of VEGF was significantly higher in RT treated rats
in both tumor rim and core (Table 5.3). The pimonidazole hy-
poxia score, however, did not significantly differ between RT
treated and control animals. In the tumor rim, mean MVD was
lower in RT treated animals, but the difference did not reach sta-
tistical significance. In the tumor core, MVD was significantly
lower compared to the tumor rim but did not differ between
control and RT treated animals.
5.4.6 Correlation of DCE-MRI Parameters with
pO2 and Histology
After RT, pO2 in the tumor rim was inversely related to Ktrans
(r = -0.57, p = 0.09) and Ve (r = -0.65, p = 0.04) (Figure 5.10).
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Controls RT p
VEGF mean score rim 2 5 0.005
core 2 5 0.018
Hypoxia median score rim 4 3.5 0.33
core 4.5 4 0.79
MVD mean rim 16.9 10.4 0.061
core 5.3 6.1 0.33
Table 5.3: Immunohistochemistry scores in the tumor rim and core in con-
trol and irradiated animals. MVD, mean vessel density; RT, radiotherapy.
No correlation, however, was found between pO2 and signal in-
tensity AUC after RT. Similarly, no significant correlations were
found between DCE-MRI parameters and histological parame-
ters (MVD, VEGF expression, pimonidazole hypoxia score).
Figure 5.10: Correlation between pharmacokinetic parameters and pO2.
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5.5 Discussion
Tumor vessels display ultrastructural abnormalities including
transcellular openings, widened interendothelial junctions, ab-
normal endothelial cells, and absent basement membrane which
increase permeability even for large molecules.[20]
In this study we examined the use of P792, a new macromolec-
ular CA to measure changes in neovascular leakage induced by
fractionated short term RT. Neovascular leakage is an important
physiological tumor parameter that has been shown to respond
quickly and dramatically to anti-angiogenesis interventions.[21]
Leakage of contrast agent is determined both by endothelial
permeability and by the total exchange surface area (propor-
tional to the number of functional vessels). Microvessel counts
were performed to differentiate permeability effects of RT from
changes in the total surface area. In order to optimize imag-
ing parameters describing the contrast agent dynamics, a high
temporal resolution scanning method was used with contrast ad-
ministered as a rapid central venous bolus.[22] DCE-MRI was
compared with invasive pO2 mapping. The fluorescence lifetime
method we have used to measure pO2 has several advantages
over the Eppendorf device, including absence of oxygen con-
sumption and increased accuracy at low oxygen tensions com-
mon in neoplastic tissue.[23] We chose to study post-RT effects
relatively early to reflect clinical practice, with surgery after
short term RT being usually performed within 1 week after the
end of therapy.
Our main finding is a significant reduction of Ktrans after short
term fractionated RT. Although the MVD did not differ sig-
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nificantly between RT treated and control animals, a trend to-
wards lower MVD in irradiated rats was present. Although the
present analysis of a small number of animals does not allow us
to draw a definitive conclusion, probably both altered endothe-
lial permeability and a change in total microvascular surface
area contribute to the decreased Ktrans after RT. Expression
of VEGF was significantly higher in RT treated rats compared
to control animals. Hypoxia as a trigger of VEGF expression
was decreased after RT in this model. However, other radiation-
induced activators of VEGF expression such as the mitogen ac-
tivated protein kinase (MAPK) pathway have been shown to
enhance VEGF expression following RT.[24] Overexpression of
VEGF after RT has also been clinically demonstrated in rectal
cancer patients.[25]
Published experimental data suggest that, depending on the
dose and fractionation of RT and the timing of permeability
measurement, neovascular permeability can be either increased
or decreased.[26] Large, single RT doses disrupt the endothelial
lining and cause a short term increase in endothelial permeabil-
ity. Smaller or fractionated doses, however, tend to decrease
vacular permeability or cause no change in this parameter. Sev-
eral authors have used DCE-MRI to study the effects of RT
on microvascular phyiology. Yu et al. used DCE-MRI with
gadopentetate dimeglumine (Gd-DTPA) and the macromolec-
ular CA gadomer-17 to study microvascular permeability in a
rat adenocarcinoma model.[27] They observed a 67% decrease in
permeability measured using gadomer-17 at 3 days after a single
dose of 5 Gy, while no change was observed after a dose of 20
Gy. No changes in permeability were observed with either dose
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of RT when Gd-DTPA was used as a contrast agent. Kobayashi
et al. studied neovascular permeability with a macromolecu-
lar CA after a single dose of RT or fractionated RT.[28] They
found an increased permeability after a single dose of 15 Gy,
while permeability was unaffected by fractionated RT.
Several clinical studies have used DCE-MRI with small molec-
ular weight MRI contrast agents to study tumor microenvi-
ronment during rectal cancer therapy. George et al. found a
significant relation between pretreatment Ktrans assessed with
Gd-DTPA and response to neoadjuvant chemoradiation.[29] Re-
sponsive tumors showed a marked reduction in Ktrans at the
end of treatment (mean logarithmic Ktrans -0.46 versus 0.86;
p=0.04). It should be noted that with the use of Gd-DTPA
Ktrans probably represents both permeability and microvascu-
lar flow. Gd-DTPA as a contrast agent was also used by de
Vries et al, who monitored microcirculation during chemoradia-
tion for rectal cancer.[30] They calculated a perfusion index from
the shape of the arterial and tumor tissue curves and found this
value to be significantly increased up to two week after the start
of chemoradiation. In patients treated with surgery only, Tunc-
bilek et al. found a significant relation between pretreatment
descriptive DCE-MRI parameters and microvessel density, tu-
mor grade and patient outcome.[31] We found that the biophys-
ical and imaging properties of P792 allow to selectively study
neoplastic vascular physiology and to monitor the effects of RT
on tumor microvasculature. Several authors have used P792
to characterize tumor physiology in animal models. Turetschek
et al. found no relation between transendothelial permeabil-
ity estimated with P792 and histological parameters (microves-
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sel density and tumor grade) in a breast cancer model.[32] In
a prostate cancer model, however, P792 based DCE-MRI was
successfully used to monitor changes in permeability following
anti VEGF therapy.[15] It is likely, therefore, that succesful esti-
mation of neovascular permeability with P792 is highly depen-
dent not only on imaging and image processing methodology
but also on tumor type and grade. A comparison of gadopen-
tetate dimeglumine and P792 to characterize tumor physiology
and metastatic ability in a rodent prostatic cancer was published
by Fan et al.[33] They used an empirical mathematical model
to fit the observed enhancement curves. In agreement with our
findings, uptake of P792 was slow and influenced primarily by
capillary leakage, with a strong uptake difference between tumor
and normal tissue.
We combined DCE-MRI with invasive pO2 measurements, and
found a significant increase in pO2 in the peripheral region of
the tumor that was sampled with a fiberoptic probe. The avail-
able evidence concerning the effect of fractionated radiation on
tumor oxygenation suggests that either an increase or a decrease
in oxygenation can be observed depending on RT dose, fraction-
ation, tumor histology, and timing of pO2 measurement.[34]
Increased oxygenation shortly after fractionated radiotherapy
has been previously reported and is the net result of changes
in both oxygen supply (reduced interstitial pressure, increased
flow) and oxygen consumption (decreased cell density).[35] Our
results suggest a bimodal distribution of tumor pO2 values, a
finding previously reported in a prostate cancer model using
a noninvasive assay.[36] Oxygenation was sampled over a 4 mm
trajectory; the observed bimodal distribution therefore probably
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represents intralesion heterogeneity with severely hypoxic zones
and better oxygenated zones surrounding feeding vessels. Before
RT, no relation could be demonstrated between pO2 measure-
ments and DCE-MRI parameters in the tumor rim. After RT,
however, high pO2 values corresponded with low Ktrans and
Ve values while no relation was found with the signal intensity
AUC. This finding probably reflects the stabilizing effect of RT
on tumor vasculature with a partial return of the physiological
relationship between well oxygenated tissue and a structurally
normal microvessel wall. Moreover, our data support the use
of pharmacokinetic modeling of dynamic MRI data to gener-
ate parameters which directly reflect physiological processes in
contrast with mere description of the tissue enhancement curve.
In conclusion, the biophysical properties of P792 allow noninva-
sive measurement of microvascular leakage in a colorectal tumor
model. Fractionated RT markedly decreases contrast leakage by
altered neovascular permeability. After RT, reoxygenation of
tumor tissue corresponds with a lowered transfer constant and
leakage space. DCE-MRI could therefore be a tool in noninva-
sive monitoring of tumor microvascular response to fractionated
RT. Future work in this model will combine RT with chemother-
apy and targeted therapy.
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6.1 Abstract
Purpose: to study modulation of radiotherapy (RT) effects
on CC531 colorectal cancer microvessels by administration of
recombinant human erythropoietin (rhEPO) in a WAG/Rij rat
model.
Experimental Design: tumor bearing rats were administered
3x0.1 ml of rhEPO weekly. Five days before and after 5x5
Gy of RT, dynamic contrast enhanced (DCE) MRI was per-
formed with P792. Mathematical modelling resulted in para-
metric maps of endothelial permeability surface product (PS),
plasma flow (F), and blood volume (V). Imaging was combined
with pO2 and laser doppler flow (LDF) measurements. After the
second set of measurements, tumors were analysed for microves-
sel density (MVD), diameter and fractal dimension (MFD). Ex-
pression of VEGF, HIF-1α, Bax, and Bcl-2 was determined im-
munohistochemically.
Results: RT significantly reduced PS and V in control rats, but
not in rhEPO treated rats, while F was unaffected by RT in both
groups. Oxygenation was significantly better in rhEPO treated
animals, and RT induced a heterogeneous reoxygenation in both
groups. LDF was significantly lower following RT in the central
tumor region of control rats, while no changes in LDF were seen
in rhEPO treated rats. Microvessel diameter was significantly
larger in rhEPO animals, while MFD was lower in the tumor
core. VEGF expression was significantly lower in the rhEPO
group. No differences were observed in HIF-α, Bax, or Bcl-2
expression.
Conclusions: rhEPO results in spatially heterogeneous mod-
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ulation of RT effects on tumor microvessels. Direct effects of
rhEPO on neoplastic endothelium are likely to explain these
findings in addition to indirect effects induced by increased oxy-
genation.
6.2 Introduction
Anemia commonly occurs in colorectal cancer patients espe-
cially if they are treated with neoadjuvant radiotherapy (RT)
or chemotherapy. Anemia not only adversely affects the clinical
condition of these patients but also contributes to the devel-
opment of tumor hypoxia, recognized as a major negative de-
terminant of sensitivity to RT, chemoradiotherapy, and certain
chemotherapeutic agents.[1,2]
Recent clinical studies have shown that administration of re-
combinant human erythropoietin (rhEPO, epoetin α) increases
hemoglobin levels and improves quality of life in patients with
cancer related anemia.[3] Over the last decade it has become
clear that the action or rhEPO extends into a wide range of
cellular mechanisms involved in stem cell development, mainte-
nance of cellular integrity, and physiological angiogenesis.[4] The
demonstration of the EPO receptor in various neoplastic tis-
sues and the observation in a recent clinical trial that mortality
was higher in non-anemic rhEPO treated breast cancer patients
highlighted the possible effects of rhEPO on tumor growth and
angiogenesis.[5] Preclinical studies investigating the role of EPO
and EPO - EPO receptor signalling on tumor growth and angio-
genesis have yielded contradictory results. Yasuda et al. noted
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inhibition of angiogenesis and tumor cell survival in stomach and
melanoma xenografts following blockade of EPO signalling.[6]
The results of Hardee et al., however, suggested that adminis-
tration of rhEPO did not affect angiogenesis or tumor growth
in human colon and head and neck xenografts.[7]
The importance of tumor oxygenation for RT response is well
established, and there has been considerable interest in modu-
lating tumor oxygenation and RT response by rhEPO admin-
istration. Experimentally, exogenous rhEPO has been shown
to improve or restore radioresponsiveness in both anemic and
non-anemic animals.[8-10] Interestingly, darbepoetin α, an EPO
analogue with a longer half-life, did not enhance radiorespon-
siveness in a rat mammary adenocarcinoma model.[11]
The exact mechanism by which rhEPO exerts its effects on tu-
mor oxygenation is at present unclear. Indeed, recent data sug-
gest that this effect may be independent of changes in hemoglobin
and mediated by changes in vascular endothelial growth factor
(VEGF) expression and microvessel morphology.[12,13]
We aimed to further characterize the effects of rhEPO on mi-
crovascular morphology and function in non-anemic rats using a
novel imaging methodology. We previously used dynamic con-
trast enhanced magnetic resonance imaging (DCE-MRI) with
a macromolecular contrast agent to demonstrate a significantly
decreased neovascular leakage after fractionated RT in a rat col-
orectal cancer model.[14] DCE-MRI allows non-invasive in vivo
study of microvascular properties of a complete tumor, thereby
taking into account the important spatial heterogeneity of solid
tumors with zones of well perfused tissue as well as hypoxic or
necrotic areas.[15] We here studied the effects of rhEPO on RT-
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induced microenvironmental changes in a rat colorectal cancer
model and correlated non-invasively obtained data with invasive
oxygenation and flow measurements, microvessel density, com-
plexity and diameter, and expression of hypoxia-regulated and
apoptosis markers.
6.3 Materials and Methods
The experimental protocol was approved by the Animal Exper-
imentation Ethical Committee of the Ghent University, Ghent,
Belgium.
6.3.1 Animal and tumor model
MaleWag/Rij rats were bought from Harlan, Horst, The Nether-
lands. The CC531 cell line is a 1,2-dimethylhydrazine-induced,
moderately differentiated and weakly immunogenic colon ade-
nocarcinoma, syngeneic with WAG/Rij rats. This cell line is
well studied and has been proven to provide a tumor-host model
similar to human colorectal carcinogenesis.[16] Cells were grown
in plastic culture flasks in RPMI 1640 medium, buffered with
HEPES (20 mM) (Invitrogen Corporation, Gibco, Ghent, Bel-
gium) additionally supplemented with 10% fetal calf serum,
4mM L-glutamine, 50 U/ml penicillin and 50 g/ml streptomycin
at 37 degrees C in a humidified atmosphere with 5% CO2 in air.
The cells were transferred at 95% confluency. Two million cells
suspended in 0.2 ml of saline were injected subcutaneously in
the proximal hind leg. Tumors reached a size of 0.5-1 cm af-
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ter a period of 4 weeks. Once a tumor growth of minimally 8
mm diameter was observed, a jugular vein catheter was inserted
and tunneled to the interscapular region. In order to maintain
catheter patency, continous infusion at 0.5 ml saline per hour
was administered with a cage mounted swivel and flexible metal
tether system (Uno BV, Didam, The Netherlands) allowing the
animal full mobility.
6.3.2 Experimental therapy
Recombinant human EPO has been shown to bind to the rodent
EPO receptor.[17] Animals were randomly divided in 2 groups:
a control group (n=11) and an rhEPO group (n=15) receiving
rhEPO (Eprex, Janssen Cilag, Beerse, Belgium) at a dose of
3x0.1ml (286 IU) sc per week. The dosage was based on a dose
finding study during which five or eight rhEPO administrations
weekly resulted in an excessive hematocrit rise and important
mortality (data not shown).
Rats were longitudinally studied during three weeks using the
following timeframe: start of rhEPO administration (day 1);
first DCE-MRI, oxygenation and flow measurement (day 8);
fractionated RT 5x5 Gy (day 13-17); second DCE-MRI, oxy-
genation and flow measurement, and sacrification by anesthesia
overdose and excision of tumors for histology (day 22).
6.3.3 Radiotherapy
Rats were not sedated and the tumor bearing hind leg was im-
mobilized using a plexiglass holder, as described previously.[18,19]
156
Briefly, rats were placed in a purpose-built plexiglass holder in
prone position. The hind legs were pulled through an opening
in the holder and immobilized. Before each fraction, a radiation
field was simulated encompassing the tumor with a margin of 1.5
cm. The photon irradiation was performed with a 5 MV linear
accelerator (Elekta, Crawley, UK). Five fractions of 5 Gy (total
dose 25 Gy) were delivered on five consecutive days. Since the
tumors were inoculated subcutaneously, they were covered with
tissue-equivalent silicone bolus of 1 cm to prevent the build-up
effect under the skin. One single direct field at a fixed source-
skin distance of 100 cm was used. The dose was calculated to
the midpoint of the tumors according to their volume in each in-
dividual animal, as obtained during simulation. DCE-MRI and
oxygenation measurements were performed 5 days before and 5
days after the completion of RT.
6.3.4 Magnetic Resonance Imaging
The principle of DCE-MRI consists of serial measurements of
signal intensity changes in both tumor tissue and a feeding
artery after bolus injection of a paramagnetic contrast agent
(CA). Depending on the physical properties of the CA and the
leakiness of the microvessel wall, a fraction of the CA will reach
the interstitial space of the tumor where an increase in signal
intensity over time will be observed. After translation of signal
intensity changes to CA concentration values, pharmacokinetic
modelling allows calculation of physiological properties such as
microvessel permeability and tumor blood volume.
Dynamic contrast studies were performed with P792, a new
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monogadolinated rapid clearance MRI blood-pool CA which
is cleared by renal elimination. The molecular weight of the
compound is 6.47 kDa, but the mean diameter of P792 is 50.5
Angstrom and the T1 relaxivity of this agent is 29 mM-1 s-1 at
60 MHz.[20] The apparent hydrodynamic volume of P792 is 125
times greater than that of Gd-DOTA (gadoterate meglumine,
Dotarem) and as a result of this high molecular volume, P792 is
characterized by a limited diffusion across normal endothelium
and therefore ideally suited to study hyperpermeable neoplastic
vessels.[21]
Experimentally, P792 has been used to study permeability ef-
fects of anti-angiogenesis therapy in a prostate cancer model.[22]
We have previously demonstrated that P792 selectively enhances
tumor tissue in this colorectal cancer model.[14] T1 weighted
DCE-MRI was performed on a Siemens Magnetom Symphony
1.5 Tesla scanner (Siemens AG, Erlangen, Germany). Animals
were sedated with 0.2-0.4 ml of medetomidine (Domitor, Novar-
tis Animal Health, Basel, Switzerland). Imaging comprised a
single axial slice that was positioned through both lower limbs
and the center of the tumor. Prior to the contrast series, T1
zero time maps were constructed from two spin echo sequences
with different repetition times (TR 1000 ms and 318 ms, respec-
tively). Details of this sequence were as follows: slice thickness
3 mm, field of view (FOV) 140x88, matrix size 256x160, echo
time (TE) 20 ms, and flip angle 90 degrees. Dynamic imaging
was performed with a 4 antenna wrist coil (diameter 10 cm) us-
ing an inversion recovery TurboFLASH sequence. Details of the
pulse sequence were as follows: temporal resolution 1.1s, FOV
140x88, matrix size 256x160, slice thickness 5 mm, TE 4.08 ms,
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inversion time 560 ms, and flip angle: 12 degrees. A bolus of
0.3-0.4 ml of P792 was manually injected as fast as possible
(approximately 1ml/s) through a central venous line after the
fourth scan. A total of 500 images was obtained for a total scan
time of 550 seconds.
6.3.5 Tracer Kinetic Modelling
Pixel by pixel pharmacokinetic modelling of DCE-MRI data was
performed with the research mode of a dedicated software pack-
age (MIStar, Apollo Medical Imaging, Melbourne, Australia).
Extraction of both microvascular permeability and flow data
was based on the tissue homogeneity (TH) model of capillary
exchange originally described by Johnson and Wilson and later
adapted for the study of cerebral flow by St Lawrence and
Lee.[23,24] This model (Fig 6.1) consists of a plasma space, in
which the contrast agent concentration is a function of both
time and distance along the capillary unit, and an extracel-
lular extravascular space (EES) assumed to be homogenously
mixed (ie, a compartment). Leakage of contrast agent takes
place between the vascular space and EES through a semiperme-
able membrane characterized by a permeability surface product
(PS). Since P792 does not enter the intracellular compartment,
the sum of the fractional plasma volume (Vp) and fractional
extracellular volume (Ve) reached by the CA equals 100%, ie
Vp+Ve=1.
When the assumption is made that changes in EES concentra-
tion per unit time are negligible compared to changes in plasma
concentration, an adiabatic approximation to the TH model can
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be derived which has been used in modelling of DCE-MRI con-
trast agent kinetics applied to tumor microvasculature.[24,25]
The adiabatic approximation to tissue homogeneity (AATH)
model is given by superposition of the arterial input function
(AIF) with a time varying residue function:
Ce(t) = FpCa(t)⊗R(t)
where Ce (mM) is the contrast agent (CA) concentration in the
EES, Fp (unitless) is the plasma flow, R denotes the residue
function, and ⊗ the convolution operator. The time course of
CA arrival is divided in a vascular phase (t<τ , with τ the tran-
sit time through a capillary) and a tissue phase (t>τ). Depend-
ing on the time interval, the residue function will encompass a
vascular and a tissue component:
R(t) = 1 0 ≤ t < τ
R(t) = Ee
−Ktrans
ve
(t−τ) t ≥ τ
with E the extraction ratio from plasma space to EES, Ktrans
the endothelial transfer constant (min-1),Ve the fraction of the
EES available as leakage space (unitless), and τ the mean cap-
illary transit time (s). The tissue contrast agent concentration
can therefore be modelled as:
Ce = Fp
∫ τ
0
Ca(t− t′)dt′ +Ktrans
∫ t
τ
Ca(t′)e
−Ktrans
ve
(t−t′−τ)dt′
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In each animal, the pixel containing the AIF curve was selected
in the femoral artery feeding the tumor bearing limb. A region
of interest (ROI) was drawn encompassing the outer vascular
rim of each tumor. Within this ROI, a pixel by pixel curve fit-
ting routine based on the Levenberg-Marquardt minimization
method was performed generating parametric maps of the fol-
lowing parameters: Fp, PS, and the fractional plasma volume
Vp, calculated as Fp x MTT. Numerical parameter values for
each pixel were exported to a spreadsheet for statistical analysis.
6.3.6 Tissue pO2 and flow measurements
Tissue oxygenation and laser doppler flow (LDF) were mea-
sured with a fiberoptic probe combining fluorescence quench-
ing with laser doppler flowmetry (OxyLite and OxyFlo, Ox-
ford Optronix, Oxford, UK).[12,26] A precalibrated fiberoptic
probe was inserted 5 mm deep into the tumor using a Seldinger
technique; the probe was then withdrawn in 40 steps of 100
µm each over a total distance of 4 mm using a micromanip-
ulator (model MN151, Narishige International Ltd, London,
UK). After each micromanipulator movement, measurements
were started as soon as a stable reading was obtained. Tis-
sue pO2 was sampled every 2 seconds. Over this 4 mm trajec-
tory, oxygenation and LDF values were recorded separately for
the tumor core (central 1-2 mm) and peripheral angiogenic rim
(outer 1 mm). Tissue pO2 was expressed in mm Hg while LDF
was expressed in arbitrary units.
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6.3.7 Immunohistochemistry
Paraffin-embedded tissue samples were used for immunohisto-
chemistry with the following antibodies: anti-EPO receptor (M-
20) (sc-697, Santa Cruz Biotechnology Inc., Santa Cruz, Califor-
nia, USA), anti-Bcl-2 (sc-7832, Santa Cruz), anti-Bax (sc-7480,
Santa Cruz), anti-VEGF (sc-7269, Santa Cruz) and anti-HIF-
1alfa (sc-10790, Santa Cruz). Paraffin-embedded sections were
rehydrated by serial immersion in xylene and ethanol. After
rinsing, the endogenous peroxidase was blocked with 0.3% hy-
drogen peroxide. The sections were subsequently incubated with
a biotinylated secondary antibody, followed by incubation with a
streptavidin-peroxidase complex (LSAB+ kit, Dako). The color
reaction was developed using 3-amino-9-ethylcarbazole substrate
(Dako) as chromogen. Finally, the sections were counterstained
with hematoxylin. Semi-quantitative scoring was based on a
method modified after Coppola et al. with a scale ranging from
0 to 9.[27] The scale was based on scoring of the fraction of
positive cells (0: all cells negative; 1: <33% positive; 2: 33-
66% positive; 3: >66% positive) and the staining intensity (1:
weak; 2: moderate; 3: intense). Both scores were multiplied to
a maximum score of 9. Scoring was performed separately on the
tumor core and peripheral tumor rim.
6.3.8 Microvascular Density and Diameter
Microvascular density (MVD) was determined with a method
modified after Weidner et al.[28] After incubating 5 µm frozen
slices with anti-CD31 antibodies (TLD-3A12, Serotec, Oxford,
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UK), the entire tumor section was scanned at low power (objec-
tive, 4 X) to identify ‘hot spots’, which are the areas of highest
neovascularization. Individual microvessels were then counted
under higher power (objective, 40 X) to obtain a vessel count in
a defined area, and the average vessel count in 3 hot spots was
taken as the MVD.
Microvascular diameter was measured on digitized CD31 stained
slices (objective, 10 X). From each rat, five different zones were
analysed and the largest diameter measured from all visible mi-
crovessels using NIH ImageJ software (version 1.35p, available
from http://rsb.info.nih.gov/ij).
6.3.9 Microvessel Fractal Dimension
The tumor associated microvascular network can be considered
as a complex architecture defined not only by the number of
microvessels but also by the degree of branching, tortuosity and
irregularity. Fractal analysis of two dimensional histology slides
has been shown to provide additional information on tumor mi-
crovascular complexity.[29,30] Whereas classical geometrical ob-
jects are usually associated with integer values for a dimension
(1 for a line, 2 for a square), complex biological structures are
best defined by a fractal dimension that is a rational number
between 1 and 2. The more complex (branched, tortuous) the
microvascular structure, the closer the fractal dimension is to
2. From each tumor, digital images were obtained from five
CD31 stained tumor hot spots (objective, 10 X) and analysed
with ImageJ software. By applying a color threshold, non CD31
stained pixels were removed from the image. The microvessel
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fractal dimension (MFD) was calculated using the box counting
method. The image is divided into increasingly smaller boxes,
and after each step the number of non empty boxes is counted.
The fractal dimension is calculated as
D = lim
ε→0
logN(ε)
log(1/ε)
with  the length of a box side, and N () the smallest number of
boxes required to contain all CD31 stained pixels. In practice,
the limit of a box sized 0 cannot be applied and therefore the
MFD was calculated as the slope of the curve fitted after plotting
log N () versus log (1/). Calculations were performed with the
fractal dimension plugin available in the ImageJ environment.
6.3.10 Statistical Analysis
Data are expressed as mean standard error of the mean, un-
less stated otherwise. Differences between 2 groups of continu-
ous data were analysed with the Student t-test or, when data
distribution was non Gaussian, with the non-parametric Mann
Whitney U test while differences between fractions were evalu-
ated with the Chi square or Fisher exact test. Statistical signifi-
cance was assumed when p ≤ 0.05. All calculations and plotting
were performed with SigmaStat software (version 3.11, Systat
Software, Richmond, USA).
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6.4 Results
6.4.1 Expression of the EPO Receptor
All tumors showed expression of the EPO-R on neoplastic cells
and neoplastic endothelium (Fig 6.2). There was no difference
in expression score between control and rhEPO treated animals.
In both groups, however, EPO-R immunoreactivity was signifi-
cantly higher in the tumor core compared to the vascular tumor
rim.
Figure 6.2: Immunoreactivity of the erythropoietin receptor. A, represen-
tative immunohistochemistry showing both cytoplasmatic and membrane
staining of tumor cells and endothelial cells (arrow). Bar, 25 µm. B, com-
parison of EPO-R immunoreactivity scores in the tumor rim and core of
both control and rhEPO treated animals. Columns, mean; Bars, standard
error; *p < 0.001 versus the tumor core.
166
6.4.2 Effects of rhEPO on Hematocrit
Hematocrit values were tested before starting the experiment
and on day 8 (immediately before the first MR imaging and oxy-
genation measurements). In rhEPO treated rats, mean hemat-
ocrit showed a 25% increase from 50.7% ± 0.4% before therapy
to 62.6% ± 0.4% on day 8 (p < 0.001, Student t test). In the
control group, hematocrit values remained unchanged.
6.4.3 Effects of rhEPO on Tumor Growth
The present experiment was intended to detect early microvas-
cular changes after fractionated RT and not to study the effects
of rhEPO on tumor growth or modulation of RT effects on tu-
mor growth. Administration of rhEPO was therefore started
after a tumor had developed. Tumor volume before RT was 1
cm3 ± 0.2 cm3 in the control group and 0.97 cm3 ± 0.11 cm3
in the rhEPO group (p = 0.79, Mann Whitney U test). After
RT, tumor volume was 0.99 cm3 ± 0.2 cm3 in the control group
and 0.99 cm3 ± 0.16 cm3 in the rhEPO group (p = 0.99, Mann
Whitney U test).
6.4.4 Effects of rhEPO on RT Induced Mi-
crovascular Changes
Pixel by pixel kinetic modelling encompassing both the tumor
core and rim was performed with estimation of 3 microvascular
parameters: plasma flow Fp, permeability surface product PS,
and fractional plasma volume Vp.
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Results of DCE-MRI microvascular data modelling are shown in
Fig 6.3. Microvascular plasma flow in the tumor core of control
rats was significantly lower after RT (p < 0.001, Student t test).
No significant effect of RT was noted in the tumor rim of control
animals. In rhEPO treated rats, microvascular flow in the tumor
core was also significantly lower after RT (p < 0.001, Student
t test) but unaffected in the tumor rim. The magnitude of the
RT effect on tumor core flow did not differ significantly between
control and rhEPO treated animals (33% versus 23% decrease
respectively, p = 0.11, Fisher exact test). In control animals, the
microvessel permeability surface product (PS) was significantly
lowered by RT in the tumor rim (p < 0.001, Student t test) but
not in the tumor core. In rhEPO treated animals, however, PS
was not affected by RT.
Fractional plasma volume was significantly lower in both the
tumor core and rim in control animals after RT (p < 0.001,
Student t test). In rhEPO treated animals, however, no signifi-
cant changes in plasma volume were noted after RT.
6.4.5 Effects of rhEPO on Oxygenation and
Flow
Oxygenation and laser Doppler flow measurements were per-
formed before and 5 days after completion of fractionated RT.
Mean pO2 values in the tumor core and peripheral rim before
and after RT in both groups are shown in Fig 6.4 A and B. Oxy-
genation was significantly better in the tumor rim compared to
the tumor core of all animals (data not shown). In the con-
trol group, RT induced a reoxygenation in the tumor core (p
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= 0.067, Student t test) but not in the tumor rim (p = 0.36,
Student t test). In the rhEPO group, on the contrary, no sig-
nificant difference in oxygenation was observed in the tumor
core (p = 0.12, Student t test) while a significant increase in
pO2 was observed in the tumor rim (p = 0.032, Student t test).
Both before and after RT, pO2 values were significantly higher
in rhEPO treated rats in both regions of the tumor (data not
shown). Mean LDF values (arbitrary units) are illustrated in
Fig 6.4 C. In all animals, LDF was significantly higher in the
tumor rim compared to the tumor core. In the control group,
RT significantly decreased LBF in the tumor core (p = 0.023,
Student t test) but not in the tumor rim. In the rhEPO group,
however, RT did not influence LDF in either tumor zone. Before
RT, LDF measured in the tumor core was significantly lower in
rhEPO treated animals (p = 0.014, Student t test) compared to
controls while no significant difference was present in the tumor
rim. After RT, LDF values in both tumor core and rim were
not significantly different between control and rhEPO treated
animals (data not shown).
6.4.6 Effects of rhEPO on Microvessel Density
Mean microvascular density (MVD) was 12.5± 1.2 in the control
group and 14.3 ± 1.4 in the rhEPO group (p = 0.35, Student
t test). Within each group, MVD was significantly lower in the
tumor core compared to the tumor rim (12.5 ± 1.2 versus 7.3
± 0.6, p < 0.001 in the control group and 14.3 ± 1.4 versus 6.6
± 0.5, p < 0.001 in the rhEPO group, Student t test).
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6.4.7 Effects of rhEPO on Microvessel Fractal
Dimension and Diameter
Microvessel morphology data are illustrated in Fig 6.5. Mi-
crovessel fractal dimension was spatially heterogeneous. In the
tumor core, MFD was significantly lower in rhEPO treated an-
imals (p = 0.006, Student t test). In the tumor rim, however,
MFD did not differ between control and rhEPO animals (p
= 0.62, Student t test), Fig 6.5 C. Overall microvessel diam-
eter (µm) in tumor tissue was 55.9 ± 2.1 in the control group
and 75.4 ± 2.7 in the rhEPO group, p < 0.001. The increased
microvessel diameter in rhEPO treated animals was more pro-
nounced in the tumor core (p < 0.001, Student t test) than in
the tumor rim (p = 0.07, Student t test), Fig 6.5 D.
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Figure 6.5: Comparison of tumor microvessel fractal dimension and diame-
ter in control and rhEPO treated rats. A and B, examples of CD31 stained
microvessels in the tumor core of control and rhEPO treated animals. Bar,
25 µm. C, microvessel fractal dimension in the tumor core and rim in con-
trol and rhEPO treated animals. Columns, mean; Bars, standard error; *p
= 0.006. D, microvessel diameter in the tumor core and rim in control and
rhEPO treated animals. Columns, mean; Bars, standard error; *p < 0.001;
**p = 0.07.
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6.4.8 Effects of rhEPO on Expression of VEGF,
HIF-1alfa, Bax, and Bcl-2
Immunohistochemistry data are summarized in Fig 6.6. Total
VEGF expression score was significantly higher in the control
group (p = 0.048, Mann Whitney U test). Within each group,
the difference in VEGF expression in the tumor core versus tu-
mor rim was not significant. Total expression of HIF1α did
not differ significantly between both groups (p = 0.78, Mann
Whitney U test). There was also no significant difference in
expression of Bax (p = 0.21, Mann Whitney U test test) or
Bcl-2 (p = 0.72, Mann Whitney U test) between control and
rhEPO treated animals. In rhEPO treated animals, Bcl-2 ex-
pression was significantly lower in the tumor core compared to
the tumor rim (p = 0.012, Mann Whitney U test ).
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Figure 6.6: Expression of hypoxia regulated and apoptosis related markers.
A and B, example of VEGF staining intensity in control and rhEPO treated
animals. Bar, 50 µm. C-F, expression of VEGF, HIF-1α, Bax, and Bcl-2
in the tumor peripheral rim (P), core (C), and total score. Columns, mean;
Bars, standard error; *p =0.048; **p = 0.012.
175
6.5 Discussion
The presence of hypoxia adversely affects radiotherapy response
and prognosis in cancer patients.[31] Since the oxygen carrying
capacity is mainly determined by the blood hemoglobin concen-
tration, pharmacological manipulation aiming to restore or in-
crease hemoglobin levels have received considerable interest in
cancer patients undergoing RT or chemotherapy. Erythropoi-
etin is a pleiotropic hormone whose biological role has recently
been shown to extend not merely to the hematopoietic tissues
but also to the neuronal and cardiovascular systems, where it
exerts a cytoprotective effect.[4] Administration of exogenous
rhEPO not only improved quality of life but increased survival
in a number of clinical studies in solid tumors.[32,33] On the
other hand, EPO has been shown to exert direct effects on an-
giogenesis and tumor growth mediated by presence of the EPO
receptor on endothelial cells and a number of malignant cell
types.[34,35] Preclinical studies investigating the effect of exoge-
nous rhEPO on tumor growth and angiogenesis are at present
inconclusive.[7] Similarly, while some preclinical data suggest
that rhEPO increases response to RT, chemotherapy or photo-
dynamic therapy, other studies did not identify any effects of
rhEPO.[8,10,11] We aimed to study how rhEPO modulates the
early in vivo effects of RT on colorectal cancer microvasculature.
Undoubtedly, modulation of RT effects is mediated by both in-
creased oxygenation and direct effects of rhEPO on normal and
tumor microvessels. Moreover, solid tumors are characterized
by an important heterogeneity with both well oxygenated and
hypoxic or necrotic regions. Therefore, non-invasive functional
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imaging was used that allows differentiating between different
tumor regions. Expression of the EPO-R was present in all tu-
mors and significantly more pronounced in the highly vascular
tumor rim. There is at present no clearly defined relationship
between tumor hypoxia and expression of the EPO receptor by
cancer cells. In head and neck cancer patients, Arcasoy et al.
found a positive correlation between tumor hypoxia and EPO-
R expression while others did not observe any correlation in a
similar patient cohort.[36-38] The experiment was not intended
to study changes in macroscopic tumor growth. We analysed
rhEPO mediated modulation of tumor cell sensitivity to apop-
tosis. In contrast to the findings of Batra et al., we did not
observe any difference in expression of apoptotoc or anti - apop-
totic markers between rhEPO treated animals and controls.[39]
The spatial distribution of apoptotic events did, however, differ
in rhEPO treated animals. In contrast to control animals, Bcl-2
expression in rhEPO treated animals was significantly different
between tumor rim and core suggesting an increased efficacy
of RT in the central region of the tumor by administration of
rhEPO. Dynamic MRI with a macromolecular contrast agent
is a validated technique to provide a comprehensive assessment
of tumor microvascular physiology.[40,41] Pharmacokinetic two
compartment modelling of DCE-MRI data was performed on
regions of interest encompassing the tumor vascular rim and
the tumor central core. Microvascular plasma flow was signifi-
cantly decreased by RT in the tumor core (but not in the tumor
rim) of both control and rhEPO treated animals. In keeping
with previous preclinical and clinical findings [14], 5x5 Gy of
RT decreased endothelial permeability (a surrogate marker for
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angiogenesis) in the vascular tumor rim of control animals. In
rhEPO treated animals, however, endothelial permeability was
unaffected by RT. Similarly, while the tumor vascular volume
was significantly lower after RT in both the tumor core and rim
of control animals, no changes were present in rhEPO treated
animals. This difference in response could be explained both by
the previously described direct angiogenic potential of rhEPO
counteracting the effect of RT and by the ability of rhEPO to
remodel microvessels by an increase in diameter as confirmed by
the microscopy data (cfr infra).[13,35] This modulation of RT
effects was accompanied by a significantly lower expression of
VEGF in rhEPO treated animals, a finding previously reported
in colorectal xenografts.[13] Since no difference in HIF-1α ex-
pression was noted, the difference in VEGF expression is likely
to result both from better oxygenation of the tumor rim and
from direct effects of rhEPO on VEGF expression. Radiother-
apy itself has been shown to induce changes in tumor tissue
oxygenation. After a single dose of 20 Gy, Ljungkvist et al.
observed a significant decrease in hypoxic fraction in a murine
adenocarcinoma model.[42] We found the increase in oxygena-
tion after 5x5 Gy to be spatially heterogenous. Interestingly,
in rhEPO treated animals reoxygenation after RT mainly oc-
curred in the tumor rim while in control animals reoxygenation
of the core was more pronounced. Administration of rhEPO
resulted in a significantly better oxygenation in both tumor re-
gions compared to control animals. This effect is attributable
to an increased blood oxygen carrying capacity and has been
observed in other preclinical models.[10]
Erythrocyte flux was measured with the laser Doppler shift
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method and, in contrast to the modelled plasma flow, pro-
vides additional information on rheological properties of the mi-
crovasculature. The observed lower LBF in the central region of
rhEPO treated animals might be explained by a higher viscosity
paralleling the difference in hematocrit.
In keeping with others [7], we were unable to demonstrate any
effect of rhEPO on angiogenesis, as reflected by the similar MVD
in both groups. Density of microvessels, however, is only one
functional aspect of a tumor microvascular bed. Aspects such
as morphology (tortuosity, branching pattern, microvessel diam-
eter), maturation and endothelial wall permeability represent
equally important attributes. We found a significantly larger
microvessel diameter in rhEPO treated rats. Moreover, the mi-
crovessel fractal dimension was significantly lower in the central
region of rhEPO treated rats, suggesting a lower spatial mi-
crovessel complexity.[43] These findings confirm the observation
of Tovari et al. that rhEPO can ‘remodel’ tumor microvessels al-
though their density seems unaffected.[13] The exact mechanism
likely involves direct action of rhEPO on the endothelium rather
than indirect effects mediated through changes in oxygenation,
since VEGF expression was significantly lower in rhEPO treated
compared to control animals.
In conclusion, the effects of RT on colorectal tumor microvas-
cular physiology are spatially heterogeneous and modulated by
administration of rhEPO. Treatment with rhEPO prevented RT
induced changes in microvascular permeability and tumor vas-
cular volume, accompanied by a larger microvessel diameter and
altered spatial complexity compared to control animals. It is at
present unclear whether this microvascular modulation increases
179
or counteracts the antitumoral efficacy of RT in this model.
However, since rhEPO resulted in an increased oxygenation of
the tumor rim, radiation response of the clonogens is likely to
be increased by rhEPO, as described by others.[10]
Further preclinical experiments will have to elucidate the multi-
ple molecular effects of rhEPO and the interaction with RT on
tumor cells, neoplastic endothelium, and normal endothelium.
6.6 Acknowledgments
The authors are grateful to Marc Bracke and Marc Mareel for
critically reviewing the manuscript.
6.7 References
1. Harrison L, Blackwell K. Hypoxia and anemia: Factors in de-
creased sensitivity to radiation therapy and chemotherapy? Oncolo-
gist 2004;9:31-40.
2. van Halteren HK, Houterman S, Verheij C, Lemmens V, Coebergh
JWW. Anaemia prior to operation is related with poorer long-term
survival in patients with operable rectal cancer. Eur J Surg Oncol
2004;30:628-32.
3. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport
B, Grp EAS. Effects of epoetin alfa on hematologic parameters and
quality of life in cancer patients receiving nonplatinum chemother-
apy: Results of a randomized, double-blind, placebo-controlled trial.
J Clin Oncol 2001;19:2865-74.
4. Maiese K, Li FQ, Chong ZZ. New avenues of exploration for ery-
thropoietin. JAMA - J Am Med Assoc 2005;293:90-5.
180
5. Leyland-Jones B. Breast cancer trial with erythropoietin termi-
nated unexpectedly. Lancet Oncol 2003;4:459-60.
6. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et
al. Erythropoietin regulates tumour growth of human malignancies.
Carcinogenesis 2003;24:1021-9.
7. Hardee ME, Kirkpatrick JP, Shan S, Snyder SA, Vujaskovic Z,
Rabbani ZN, et al. Human recombinant erythropoietin (rEpo) has no
effect on tumour growth or angiogenesis. Br J Cancer 2005;93:1350-
5.
8. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M,
Thews O, et al. Erythropoietin restores the anemia-induced reduc-
tion in radiosensitivity of experimental human tumors in nude mice.
Int J Radiat Oncol Biol Phys 2003;55:1358-62.
9. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. En-
hanced radiosensitivity in experimental tumours following erythro-
poietin treatment of chemotherapy-induced anaemia. Br J Cancer
1998;78:752-6.
10. Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin JL, Delmas
C, Plenat F, et al. Erythropoietin-induced reduction of hypoxia be-
fore and during fractionated irradiation contributes to improvement
of radioresponse in human glioma xenografts. Int J Radiat Oncol
Biol Phys 2004;59:250-9.
11. Kirkpatrick JP, Hardee ME, Snyder SA, Peltz CM, Zhao YL,
Brizel DM, et al. The effect of darbepoetin alfa on growth, oxygena-
tion and radioresponsiveness of a breast adenocarcinoma. Radiat Res
2006;165:192-201.
12. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell
F, Jolliffe L, et al. Human recombinant erythropoietin significantly
improves tumor oxygenation independent of its effects on hemoglobin.
Cancer Res 2003;63:6162-5.
13. Tovari J, Gilly R, Raso E, Paku S, Bereczky B, Varga N, et
181
al. Recombinant human erythropoietin alpha targets intratumoral
blood vessels, improving chemotherapy in human xenograft models.
Cancer Res 2005;65:7186-93.
14. Ceelen W, Smeets P, Backes W, Van Damme N, Boterberg T,
Demetter P, et al. Noninvasive monitoring of radiotherapy-induced
microvascular changes using dynamic contrast enhanced magnetic
resonance imaging (DCE-MRI) in a colorectal tumor model. Int J
Radiat Oncol Biol Phys 2006;64:1188-96.
15. Hylton N. Dynamic Contrast-Enhanced Magnetic Resonance
Imaging as an Imaging Biomarker. J Clin Oncol 2006;24:3293-8.
16. Hagenaars M, Koelemij R, Ensink NG, van Eendenburg JDH,
van Vlierberghe RLP, Eggermont AMM, et al. The development of
novel mouse monoclonal antibodies against the CC531 rat colon ade-
nocarcinoma. Clin Exp Metastasis 2000;18:281-9.
17. Okano M, Suga H, Masuda S, Nagao M, Narita H, Ikura K, et
al. Characterization of Erythropoietin Isolated from Rat Serum -
Biochemical-Comparison of Rat and Human Erythropoietins. Biosci
Biotech Bioch1993;57:1882-5.
18. Ceelen W, El Malt M, Cardon A, Berrevoet F, De Neve W,
Pattyn P. Influence of preoperative high-dose radiotherapy on post-
operative outcome and colonic anastomotic healing - experimental
study in the rat. Dis Colon Rectum 2001;44:717-21.
19. El-Malt M, Ceelen W, De Meerleer G, Verstraete A, Boter-
berg T, Van Belle S, et al. Influence of preoperative combined ra-
diochemotherapy on surgical outcome and colonic anastomotic heal-
ing: experimental study in the rat. Int J Radiat Oncol Biol Phys
2001;50:1073-8.
20. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E,
et al. Physicochemical and biological evaluation of P792, a rapid-
clearance blood-pool agent for magnetic resonance imaging. Invest
Radiol 2001;36:445-54.
182
21. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee
JM, et al. P792: a rapid clearance blood pool agent for magnetic
resonance imaging: preliminary results. Magn Reson Mater Phy
2001;12:121-7.
22. Pradel C, Siauve N, Bruneteau G, Clement O, de Bazelaire C,
Frouin F, et al. Reduced capillary perfusion and permeability in hu-
man tumour xenografts treated with the VEGF signalling inhibitor
ZD4190: an in vivo assessment using dynamic MR imaging and
macromolecular contrast media. Magn Reson Imaging 2003;21:845-
51.
23. Johnson JA, Wilson TA. A model for capillary exchange. Am J
Physiol 1966;210:1299-303.
24. St Lawrence KS, Lee TY. An adiabatic approximation to the
tissue homogeneity model for water exchange in the brain: I. Theo-
retical derivation. J Cereb Blood Flow Metab 1998;18:1365-77.
25. Henderson E, Sykes J, Drost D, Weinmann HJ, Rutt BK, Lee
TY. Simultaneous MRI measurement of blood flow, blood volume,
and capillary permeability in mammary tumors using two different
contrast agents. J Magn Reson Imaging 2000;12:991-1003.
26. Brurberg KG, Graff BA, Olsen DR, Rofstad EK. Tumor-line spe-
cific pO(2) fluctuations in human melanoma xenografts. Int J Radiat
Oncol Biol Phys 2004;58:403-9.
27. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC,
Nicosia SV, et al. Analysis of p53, p21(WAF1), and TGF-beta 1 in
human ductal adenocarcinoma of the pancreas - TGF-beta 1 protein
expression predicts longer survival. Am J Clin Pathol 1998;110:16-
23.
28. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogen-
esis and metastasis - correlation in invasive breast carcinoma. New
Engl J Med 1991;324:1-8.
29. Dey P. Basic principles and applications of fractal geometry in
183
pathology - a review. Anal Quant Cytol Histol 2005;27:284-90.
30. Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick MB.
Microscopic analysis and significance of vascular architectural com-
plexity in renal cell carcinoma. Clin Cancer Res 2001;7:533-7.
31. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the
cancer patient. Int J Radiat Oncol Biol Phys 2005;63:25-36.
32. Munstedt K, Volzing M, Von Georgi R. Hemoglobin levels during
radiation therapy and their influence on local control and survival of
patients with endometrial carcinoma. Oncology Rep 2004;11:711-7.
33. Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I,
Kilic E, et al. Epoetin alfa improves survival after chemoradiation
for stage III esophageal cancer: final results of a prospective obser-
vational study. Int J Radiat Oncol Biol Phys 2006;65:459-65.
34. Jelkmann W, Wagner K. Beneficial and ominous aspects of the
pleiotropic action of erythropoietin. Ann Hematol 2004;83:673-86.
35. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH.
Erythropoietin and VEGF exhibit equal angiogenic potential. Mi-
crovasc Res 2002;64:326-33.
36. Winter SC, Shah KA, Campo L, Turley H, Leek R, Corbridge
RJ, et al. Relation of erythropoietin and erythropoietin receptor
expression to hypoxia and anemia in head and neck squamous cell
carcinoma. Clin Cancer Res 2005;11:7614-20.
37. Hoogsteen IJ, Peeters WJM, Marres HAM, Rijken PFJW, van
den Hoogen FJA, van der Kogel AJ, et al. Erythropoietin receptor
is not a surrogate marker for tumor hypoxia and does not correlate
with survival in head and neck squamous cell carcinomas. Radiother
Oncol 2005;76:213-8.
38. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh
JA. Erythropoietin and erythropoietin receptor expression in head
and neck cancer: relationship to tumor hypoxia. Clin Cancer Res
2005;11:20-7.
184
39. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric
tumor cells express erythropoietin and a functional erythropoietin
receptor that promotes angiogenesis and tumor cell survival. Lab
Invest 2003;83:1477-87.
40. Preda A, van Vliet M, Krestin GP, Brasch RC, van Dijke CF.
Magnetic resonance macromolecular agents for monitoring tumor mi-
crovessels and angiogenesis inhibition. Invest Radiol 2006;41:325-31.
41. Jackson EF, Esparza-Coss E, Bankson A, Coxon A, Patel V,
Kendall R, et al. The effect of AMG 706, a novel tyrosine kinase
inhibitor, on vascular permeability and blood flow as assessed by dy-
namic contrast enhanced magnetic resonance imaging (DCE-MRI) in
an in vivo preclinical tumor model. Clin Cancer Res 2005;11:9037s.
42. Ljungkvist ASE, Bussink J, Kaanders JHAM, Wiedenmann NE,
Vlasman R, van der Kogel AJ. Dynamics of hypoxia, proliferation
and apoptosis after irradiation in a murine tumor model. Radiat Res
2006;165:326-36.
43. Grizzi F, Russo C, Colombo P, Franceschini B, Frezza EE, Cobos
E, et al. Quantitative evaluation and modeling of two-dimensional
neovascular network complexity: the surface fractal dimension. BMC
Cancer 2005;5:14.
185
186
Chapter 7
General Discussion
Colorectal cancer is a frequent malignancy in both men and
women, and the ageing of the population will likely give rise to
an important incidence increase in the decades to come. De-
spite efforts to introduce screening programs, most patients are
diagnosed in a locally advanced stage of the disease. Locally ad-
vanced rectal cancer continues to present a technical challenge
for surgical oncologists. In order to improve both local results
and long term outcome, most patients are now treated in a mul-
timodality fashion involving surgeon, radiotherapist, and oncol-
ogist. The aim of this work was to contribute to clinical and
experimental aspects of multimodal therapy in rectal cancer. In
chapter three, a systematic review of the literature on adju-
vant and neoadjuvant therapy regimens is provided. From both
expert series and national training programs, it is clear that
improvements in surgical technique have resulted in important
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improvements not only in LR rate but also in functional out-
come and long term survival. In Belgium, national registry data
indicated that, compared to published outcome data, important
improvements can be achieved in terms of permanent colostomy
rate, local recurrence rate, and long term survival.[1] This find-
ing was the impetus for the ProCare (Project for Cancer of the
Rectum) initiative, a nation wide training program of quality
control and improvement involving surgeons, pathologists, and
radiation oncologists. Meta-analyses have shown that preoper-
ative RT alone significantly improves LR rate and marginally
improves survival, provided the biologically equivalent dose ad-
ministered is at least 30 Gy. Many of the large trials have used
5x5 Gy of RT immediately followed by surgery. While con-
venient for the patient and proven to be efficient, this short
schedule does not allow to obtain downsizing and downstaging
while the large dose per fraction can induce considerable early
and late toxicity. The combination of long term RT schedules
with chemotherapy initiated in the setting of unresectable rectal
cancer and was subsequently introduced in both adjuvant and
neoadjuvant therapy of locally advanced resectable disease. In
the neoadjuvant setting, numerous phase II trials using CRT
have shown a promising response while acute toxicity was gen-
erally limited. This prompted the initiation of randomized trials
comparing neoadjuvant RT alone versus neoadjuvant CRT. In
two recently published trials, preoperative treatment arms en-
compassing either 45 Gy of RT alone or 45 Gy of RT combined
with 5-FU based chemotherapy were included.[2,3] Both trials
arrived at very similar conclusions: compared to RT alone, pre-
operative CRT significantly improved tumor response and local
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control while no benefit on overall survival was seen and acute
toxicity was moderately increased. Several conclusions can be
drawn based on the currently available data. First, patients
should receive a tailored multimodal approach. In resectable
cancer without possibly compromised CRM as evaluated on pre-
operative MRI and at a distance from the sphincter apparatus,
a short course of preoperative RT is sufficient. When sphincter
preservation and/or a possibly compromised CRM is an issue,
neoadjuvant CRT with a 6-8 weeks long waiting period before
surgery should be initiated. Several questions remain, however,
and further improvements in outcome are mandatory. In the
surgical domain, important work remains to be done in rec-
tal amputation technique. Several clinical studies have demon-
strated that even after expert TME, rectal amputation is asso-
ciated with a significantly higher rate of invaded CRM and local
recurrence. A likely explanation is the ‘coning in’ at the level of
the funnel shaped pelvic floor. Wide cylindrical excision with
resection of the pelvic floor musculature might result in a lower
recurrence rate, but necessitates flap closure of the wound de-
fect.[4] The effect of tumor downstaging on the sphincter preser-
vation rate is a matter of debate. Many surgeons are reluctant
to change a pre-therapy judgement that a patient requires rectal
amputation after observation of a good clinical response; future
studies will have to determine whether this decision is safe. Im-
provements in tumor response seem highly desirable, since even
with modern CRT regimens the percentage of pCR rarely ex-
ceeds 20%. In keeping with the results obtained in the setting
of metastatic disease, the addition of targeted agents could en-
hance the efficiency of neoadjuvant CRT. The anti-VEGF agent
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bevacizumab has shown promising synergy with RT in preclini-
cal models and in a phase I study.[5] The radiosensitizing effect
of bevacizumab is based on radiosensitizion of tumor-associated
endothelial cells, and on normalization of the tumor vascula-
ture and microenvironment resulting in an increase in tumor
oxygenation and radiosensitivity. Third, anti-VEGF agents can
reduce the number of circulating endothelial cells and progen-
itor cells leading to the inhibition of recurrent tumor growth
after irradiation.[6] Moreover, since RT is known to induce ex-
pression of angiogenic mediators, bevacizumab could inhibit the
growth of micrometastases. Phase II trials incorporating tar-
geted agents into neoadjuvant CRT regimens for rectal cancer
are underway. The observed lack of benefit on overall survival in
the trials comparing neoadjuvant RT alone versus CRT, suggests
that many patients harbor systemic disease from onset that is
insufficiently addressed in the early stages of therapy. Intensi-
fication of the RT effect has been sought after by changes in
the dose, fractionation, and mode of delivery of the ionizing
radiation. Excellent results were obtained in early rectal can-
cer using a combination of external RT with endocavitary high
dose RT.[7] A number of authors have used hyperfractionated
(i.e., more than one dose daily) or hyperfractionated accelerated
RT (HART) in an effort to increase efficiency and reduce late
toxicity.[8,9] The biological rationale of accelerating RT is that
the effectiveness of ionizing radiation increases with a higher
dose rate by the prevention of malignant cell repopulation and
sublethal damage repair between fractions. On the other hand,
since the size per fraction is the main determinant of late radia-
tion effects, hyperfractionation is aimed at reducing late toxicity
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while achieving a similar tumor control.
In chapter four, a clinical study is presented comparing neoad-
juvant CRT with neoadjuvant HART in rectal cancer patients.
All patients underwent nerve sparing TME. In patients who
underwent sphincter sparing surgery, the incidence of anasto-
motic leakage was low in both groups. Experimental studies
have shown that even large doses of preoperative RT do not
adversely affect colonic anastomotic healing provided only one
limb of the anastomosis is irradiated.[10] The low anastomotic
leakage rate in our series can be attributed to the liberal use
of a temporary ileostomy, a practice shown to reduce the leak-
age rate and to mitigate the consequences of leakage following
TME.[11,12] In contrast to what would be expected theoreti-
cally, HART was associated with a significantly higher early and
late complication rate including radioenteritis and rectovaginal
fistula. As expected, the pathological response rate was signif-
icantly higher in the CRT group. This difference is probably
mainly due to the difference in waiting period following com-
pletion of neoadjuvant therapy (3.5 days in the HART group
and 42.5 days in the CRT group). Interestingly, almost one in
five irradiated tumors showed a distinct mucinous differentia-
tion, a finding previously described.[13,14] Selection of mucin
producing clones known to be relatively radioresistant could ex-
plain this finding.[15] We found a better disease free survival
in patients treated with CRT, but the retrospective nature of
the study and the difference in mean follow up time limit the
relevance of this finding.
Both RT and chemotherapy induce toxicicity, and early deter-
191
mination of tumor response could prevent unnecessary harm
to a patient receiving ineffective therapy. Moreover, with the
introduction of angiogenesis agents into the multimodal man-
agement of rectal cancer patients, early demonstration of a vas-
cular response would be of interest both in preclinical models,
drug development and patient monitoring (RECIST). Radiore-
sponsiveness is determined by a complex set of variables in-
cluding patient characteristics (age, nutritional status, medica-
tion, comorbidity), tumor related factors (size, histology, tumor
grade), and treatment-related variables (treated volume, field
size, anatomic prescription point, total dose, dose per fraction,
concomitant chemotherapy). Additionally, inherent genetic fac-
tors determine radioresponsiveness and genomic analysis has
been suggested as a tool to predict radiation response.[16] Func-
tional imaging allows visualisation and quantification of therapy
effects before changes in tumor volume occur. Metabolic (func-
tional) positron emission imaging using radioactively labelled
tracers such as 18F- fluorodeoxyglucose (FDG) has been used
to determine therapy response in cancer patients.[17] There are
several methods for evaluation of FDG-PET data. The simplest
is qualitative comparison of the location, size and intensity of
image ‘hot spots’ by calculation of the standardised uptake value
(SUV)for FDG as the product of the ratios: (activity in the le-
sion / total injected activity) x (subject size / lesion volume).
More complex methods include dynamic PET data acquisition
with calculation of the rate constant of FDG influx (Ki) using
the Patlak plot method. Several drawbacks are associated with
FDG-PET imaging as a tool to assess tumor response. First, the
repeatability of the method is uncertain, since the methods to
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calculate the SUV have not been standardized.[18] According to
the RECIST criteria, there needs to be at least a 25% measured
increase in unidimensional size to count as progressive disease
(PD), and a 30% measured decrease to count as partial response
(PR). It is therefore imaginable that changes in SUV are inter-
preted as PD or PR, while in reality they are the result of poor
test repeatability. Second, while PET imaging is highly sensi-
tive, specificity is limited by the fact that inflamed tissue, car-
diac and contracting skeletal muscle, nervous tissue, and brown
fat will also accumulate FDG. Third, since there is no demon-
strated link between glucose metabolism and vascular physiol-
ogy, the method is not well suited to specifically study vascular
effects of anticancer therapy. Magnetic resonance imaging of-
fers a superior spatial and contrast resolution, and has evolved
as the standard of care in preoperative imaging of rectal cancer
allowing accurate prediction of surgical margin involvement.[19]
In addition to MRI examination using static images, dynamic
studies following injection of a bolus of paramagnetic CA allows
morphological as well as functional microvascular characteriza-
tion of tumor tissue.[20] In chapter five, we examined the use
of DCE-MRI to assess early response to RT in a rat colorectal
model. Since we were mainly interested in microvascular per-
meability changes, a blood pool CA was chosen. Although the
MW of P792 is only 6.47 kDa, the 3D structure of the molecule
with its four extending branches causes it to behave as a macro-
molecule. The results demonstrate that P792 does not enhance
normal tissue while a slowly increasing enhancement was seen
in neoplastic tissue, with a maximal rate and extent of signal
enhancement in the vascular tumor rim. This indicates that
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P792 is a suitable DCE-MRI contrast agent in assessment of
tumor microvascular properties. The signal intensity data were
subsequently translated into CA concentrations and fitted in a
two compartment pharmacokinetic model according to Tofts.
We have used a dose and fractionation identical to those clini-
cally used, and found the endothelial transfer constant (Ktrans)
to decrease significantly following RT. When using a BPCA,
Ktrans is a measure of vascular permeability and is relatively
independent on the tumor blood flow. However, it cannot be ex-
cluded that the observed decrease in Ktrans following RT results
from changes in the density of microvessels and from changes in
blood flow as well as from a decreased permeability. Since ani-
mals were followed longitudinally, we were unable to determine
MVD (requiring excision of the tumor) before and after RT in
the same animal. However, since no significant difference in
MVD was observed between irradiated and control animals, we
assume that the observed decrease in Ktrans is mainly due to a
decrease in vessel permeability. The fact that we were unable to
demonstrate a correlation with MVD illustrates the functional
rather than morphological nature of DCE-MRI characterization
of the tumor vascular bed. Although the pharmacokinetic data
obtained with the used DCE-MRI method seem robust, sev-
eral limitations are inherent to the method. First, data are
modelled according to a mathematical model and as such are
based on a number of assumptions. It is assumed that the CA
is instantaneously homogeneously mixed in the vascular com-
partment, that no shunting is present, and that a single arterial
input can be identified. These assumptions are of course overt
simplifications of the physiological reality. Second, the assumed
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linear relation between signal intensity and CA concentration
does not always hold and this can have a major impact on the
result of modelling.[21] Third, most of the MMCA and BPCA
used in preclinical DCE-MRI vascular imaging are not (yet)
available for clinical use. Nevertheless, an increasing number of
papers has used parameter modelling of DCE-MRI data in clin-
ical studies of anticancer therapy response assessment.[22-24]
The tumor microvascular bed has been identified as an impor-
tant target and mediator of RT effects in recent years, and some
authors have even suggested the endothelial cell response to be
the primary mediator of RT effect.[25,26] The effect of RT on
endothelial cell permeability is incompletely understood. Pub-
lished experimental data suggest that, depending on the dose
and fractionation of RT and the timing of permeability mea-
surement, neovascular permeability can be either increased or
decreased. Large, single RT doses disrupt the endothelial lin-
ing and cause a short-term increase in endothelial permeabil-
ity while smaller or fractionated doses tend to decrease perme-
ability.[27] The molecular mechanisms whereby fractionated RT
decreases endothelial permeability are unknown, but could in-
clude changes in the expression of cell-cell adhesion molecules,
claudins, occludins, and other components of intercellular tight
junctions.[28,29] Also, radiation was shown to induce expression
of alpha(v)beta(3) integrin in cultured endothelial cells.[30] In
vitro, irradiated endothelial cells increased proliferation and mi-
gration of vascular smooth muscle cells by pathways including
increased expression of transforming growth factor (TGF).[31]
Interesting clinical data were obtained by Baeten et al., who ex-
amined angiogenesis related parameters in pre- and post therapy
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biopsy samples from rectal cancer patients undergoing neoadju-
vant RT or CRT.[32] They found an inhibition of endothelial cell
proliferation after RT, associated with an increased expression
of VEGF and adhesion molecules together with increased leuco-
cyte infiltration. We also found an increase in VEGF expression
in irradiated animals compared to controls, and this provides a
theoretical rationale to combine RT with angiogenesis targeting
therapy. We combined DCE-MRI with invasive pO2 measure-
ments and found a significant increase in pO2 in the peripheral
region of the tumor after RT. The available evidence concerning
the effect of fractionated radiation on tumor oxygenation sug-
gests that either an increase or a decrease in oxygenation can
be observed depending on RT dose, fractionation, tumor histol-
ogy, and timing of pO2 measurement. Enhanced oxygenation
shortly after fractionated radiotherapy has been previously re-
ported and is the net result of changes in both oxygen delivery
(reduced interstitial pressure, increased flow) and oxygen con-
sumption (decreased cell density).[33,34]
There has been a long standing interest in the relationship be-
tween tumor oxygenation and the response of solid tumors to
RT.[35] Clinical studies using needle electrode measurements of
tumor oxygenation before therapy have consistently shown tu-
mor hypoxia to be associated with resistance to therapy (RT,
chemotherapy, and surgery), increased metastatic phenotype,
and worse prognosis.[36] The molecular background of hypoxia
induced radioresistance consists in the fact that when present
intracellularly, molecular oxygen binds to DNA fragments and
renders RT induced damage irreversible. Efforts to increase tu-
mor oxygenation by hyperbaric oxygen, radiosensitizers, and
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bioreductive agents have met with a limited clinical success
rate.[37] Since many cancer patients suffer from anemia, admin-
istration of EPO might improve tumor oxygenation and hence
therapy outcome. Preclinical models have shown that admin-
istration of EPO enhances tumor oxygenation and improves
response to RT.[38,39] Conflicting results have been obtained,
however, in clinical trials studying the effect of EPO administra-
tion on RT efficiency and survival.[40] While randomized trials
in esophageal [41] and endometrial [42] cancer have shown a sur-
vival benefit in EPO treated patients, studies in head and neck
[43] and breast cancer [44] patients demonstrated an adverse
effect of EPO administration on local disease control and long
term outcome. These results combined with the demonstration
of the EPO receptor on endothelial cells and several tumor cell
types, have lead to research into the direct effects of EPO on
angiogenesis and tumor growth (Fig 7.1).
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Figure 7.1: Erythropoietin (EPO) and the EPO receptor (EPOR) pre-
vent apoptosis and cellular inflammation and preserve cellular integrity
through a series of signalling cascades including Janus-tyrosine kinase 2
(Jak2),phosphoinositide 3 kinase (PI 3-K), and protein kinase B (Akt).
Reproduced with permission from Maiese K, Li F, Chong Z. New Avenues
of Exploration for Erythropoietin. JAMA 2005;293:90-95.
At present, the results from preclinical models are conflicting.[45]
Moreover, in vitro data from Belenkov et al. suggested that
EPO induces resistance to ionizing radiation and chemotherapy,
an effect that was reversed by administration of an inhibitor of
tyrosine kinase Jak2, the main intracellular target of EPO recep-
tor binding.[46] There are at present no in vivo data regarding
the effect of EPO on radioresponsiveness of the microvascular
bed. In chapter six, we examined the modulation by recom-
binant human EPO of the response of colorectal microvessels
to fractionated RT. Immunohistochemically, intense expression
of the EPO receptor on neoplastic cells and tumor associated
endothelium was observed. In this non anemic rat colorectal
cancer model, morphological and functional microvascular dif-
ferences after RT were present between EPO treated and con-
trol animals. Specifically, EPO administration partially inhib-
ited the RT induced reduction in microvascular permeability
noted in the experiments described in chapter five. Moreover,
microvessels in the EPO group were larger in diameter while
microvascular complexity was less in the central region (where
EPO receptor expression was higher) of EPO treated tumors.
Microvessel density, however, was not different between EPO
treated and control animals. We also found a reduced expres-
sion of VEGF in EPO treated animals compared to controls
while no differences were present in the expression of HIF-1
alpha, Bcl-2, or Bax. Taken together, these results suggest a re-
modelling of colorectal cancer microvessels by EPO, as already
suggested by Tovari et al.[47] The effect of EPO on microvessels
has also been noted clinically. In patients with ischemic heart
disease, administration of EPO resulted in an increase in circu-
199
lating bone marrow derived endothelial progenitor cells resulting
in enhanced neovascularisation.[48] The molecular mechanisms
of the interaction between exogenous EPO, tumor associated
endothelial cells, and tumor stroma remain to be elucidated.
7.1 Conclusion and Future Perspectives
Neoadjuvant multimodal therapy is the standard of care in lo-
cally advanced resectable rectal cancer. When sphincter preser-
vation or possible CRM compromise is important, neoadjuvant
chemoradiation with a 6-8 weeks waiting period before surgery
results in increased tumor response and enhanced sphincter preser-
vation although overall survival is not different. Compared to
chemoradiation, neoadjuvant HART is less effective in terms of
tumor response, toxicity, and disease free survival.
DCE-MRI with the blood pool contrast agent P792 can success-
fully image and quantify physiological properties of the neoplas-
tic vascular bed. Administration of 5x5 Gy of RT results in a
significant decrease of capillary permeability and results in re-
oxygenation of tumor tissue. Exogenous EPO enhances tumor
oxygenation, prevents the RT induced decrease in capillary per-
meability and results in remodelling of the microvascular bed.
Future work of our group will include molecular MRI to im-
age angiogenesis using a paramagnetic CA designed to target
alfa(v)beta(3) integrin, expressed almost exclusively by acti-
vated endothelium. In order to correlate functional imaging
with a gold standard, in vivo fluorescence microscopy will be
used to study capillary permeability in a dorsal skinfold cham-
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ber using CA that are tagged with a fluorescent marker. Using
this in vivo imaging technology and CC531 tumor cells express-
ing green fluorescent protein (GFP), early stages of angiogenesis
and hepatic metastasis will be studies as well as the effects of
various therapeutic strategies targeting angiogenesis.
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Chapter 8
Summary
The aim of this work is to contribute clinical and experimental
data on the neoadjuvant multimodality therapy of resectable
rectal cancer. In chapter three, a systematic review of the
literature is provided. While it is clear that technical improve-
ments (TME) have dramatically lowered local recurrence rates
following rectal cancer surgery, patients with cT3 disease bene-
fit from some form of neoadjuvant therapy, as evidenced by the
Scandinavian and Dutch rectal cancer trials. When the CRM
is not at risk and the tumor is at a distance from the sphinc-
ter apparatus, neoadjuvant RT alone immediately followed by
surgery is appropriate. However, when the CRM is at risk or
possible sphincter invasion is evident, neoadjuvant CRT followed
by a waiting period of at least 6-8 weeks is indicated in order
to achieve downsizing and downstaging. Two large randomized
trials encompassed treatment arms comparing neoadjuvant RT
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alone versus neoadjuvant CRT. The addition of chemotherapy
results in a superior tumor response, translating into a lower
local recurrence rate and better local control at the expense of
moderately increased toxicity. Overall survival is not improved
by the addition of chemotherapy. Neoadjuvant CRT results in
a pCR in up to 20% of patients. With the currently available
imaging techniques, achieving a clinical CR does not preclude
surgery since residual cancer can not be excluded with certainty.
Perspectives for further improvement include the addition of an-
giogenesis targeting agents to neoadjuvant therapy regimens and
early intensification of chemotherapy in order to improve overall
survival.
Several modifications of the RT regimen have been described in
order to further increase tumor response while avoiding early
and late toxicity to normal tissue. In chapter four, we com-
pared neoadjuvant CRT with neoadjuvant HART in a clinical
study of resectable distal rectal cancer. Therapy consisted of ei-
ther 45 Gy in 25 fractions of 1.8 Gy with 5-FU based chemother-
apy followed by TME after 6-8 weeks or 41.6 Gy in 26 frac-
tions (BID) of 1.6 Gy followed by immediate TME. We found
that CRT was associated with more sphincter preserving pro-
cedures (74% (HART) versus 83.5% (CRT), p=0.013). Tumor
response was better in the CRT group, with a pCR observed
in 4% (HART) versus 18% (CRT) of the resected specimens
(p=0.002). Although no differences were observed in the anas-
tomotic leak rate, both early and late toxicity were significantly
more pronounced after HART. Disease free 5 year survival was
51% (HART) versus 62% (CRT), p=0.037 while no differences
were present in local recurrence rate or overall survival.
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Early assessment of tumor response is important in drug de-
velopment, clinical trials, and follow up of individual patients.
Functional imaging of the neoplastic vascular bed allows early
visualization and enhancement of neoadjuvant therapy. In chap-
ter five, we studied DCE-MRI with P792, a BPCA to monitor
RT induced microvascular changes in a rat CC531 colorectal tu-
mor model. A two compartment pharmacokinetic model was
used to generate parametric maps of the endothelial transfer
constant (Ktrans) and the fractional EES (Ve). Imaging before
and 5 days after RT was combined with oxygenation and flow
measurements. Microvessel density and VEGF expression were
compared with a control group of non irradiated tumors. We
found a significant reduction in Ktrans and EES fraction fol-
lowing 5x5 Gy of RT, indicating reduced capillary permeability.
Although tumor oxygenation was increased after RT, VEGF ex-
pression was significantly higher in RT treated rats compared to
controls while pimonidazole hypoxia score and MVD were not
significantly different. After RT, no significant correlation was
found between DCE-MRI parameters and histological parame-
ters. An inverse correlation was seen after RT between pO2 and
Ktrans (r = -0.57, p = 0.08) and between pO2 and Ve (r = -0.65,
p = 0.04). These data indicate that DCE-MRI could be valu-
able to visualize and quantify early response to anti-angiogenic
therapy, including RT.
Since solid tumors inevitably are hypoxic and the degree of hy-
poxia is related to RT response and outcome, several approaches
to increase tumor oxygenation have been described. In chap-
ter six, we studied the effect of exogenous recombinant EPO
on the response of a colorectal tumor to RT using a similar rat
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model. Tumors (one control group and one EPO treated group)
were irradiated with 5x5 Gy or RT. Before and 5 days after RT,
DCE-MRI was performed with compartmental modelling allow-
ing to generate parametric maps of blood volume, permeability
surface product (PS), and plasma flow. Imaging was combined
with pO2 and laser doppler flow (LDF) measurements. After
the second set of measurements, tumors were analysed for MVD,
vessel diameter, and fractal dimension (MFD), a measure of vas-
cular geometric complexity. Expression of VEGF, HIF-1 alpha,
Bax, and Bcl-2 was determined immunohistochemically. We
found that RT significantly reduced PS in control rats, but not
in rhEPO treated rats. Oxygenation was significantly better in
rhEPO treated animals, and RT induced a spatially heteroge-
neous reoxygenation in both groups. Microvessel diameter was
significantly larger in rhEPO animals, while MFD was lower in
the tumor core. VEGF expression was significantly lower in
the rhEPO group. No differences were observed in HIF-1 al-
pha, Bax, or Bcl-2. These results suggest that exogenous EPO
administration results in spatially heterogeneous modulation of
RT effects on tumor microvessels. Direct effects of rhEPO on
neoplastic endothelium are likely to explain these findings in ad-
dition to indirect effects induced by increased oxygenation. The
exact molecular mechanisms whereby EPO affects endothelium
during RT remain to be elucidated.
Future work from our group will include molecular angiogenesis
imaging using a alpha(v)beta(3) integrin specific MRI contrast
agent. Furthermore, in vivo fluorescent microscopy will be used
1. to validate MRI contrast agents as a tool to measure capil-
lary permeability and 2. to study early tumor angiogenesis and
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metastatic events using fluorescently labelled cancer cells.
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Chapter 9
Samenvatting
Het doel van dit werk is zowel een klinische als experimentele
bijdrage te leveren in de multimodale behandeling van het rec-
tumcarcinoom. In hoofdstuk drie wordt een systematisch
overzicht van de literatuur gepresenteerd. Het is duidelijk dat
een nauwkeurige chirurgische techniek (total mesorectal excision
of TME) het voorkomen van lokale recidieven na rectumresec-
tie sterk heeft verminderd. Toch is voor een cT3 tumor een
vorm van neoadjuvante behandeling aangewezen, zoals aange-
toond door de Scandinavische and Nederlandse studies terzake.
Indien de circumferentie¨le resectiemarge (CRM) niet bedreigd is
en de tumor zich op afstand van de sluitspier bevindt, volstaat
neoadjuvante radiotherapie (RT) met onmiddellijke chirurgie.
Indien echter de CRM bedreigd is en/of de tumor zich dicht bij
de sluitspier bevindt, is een lange kuur RT gecombineerd met
chemotherapie aangewezen gevolgd door chirurgie na 6-8 weken
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teneinde de tumor toe te laten in grootte (en stadium) af te ne-
men. Twee grote klinische studies vergeleken neoadjuvante RT
alleen met neoadjuvante chemoradiatie (CRT). Het toevoegen
van chemotherapie bleek de tumorrespons op RT te verhogen,
hetgeen zich vertaalde in een groter aantal sphinctersparende in-
grepen en een lagere kans op lokaal recidief. De acute toxiciteit
was evenwel wat hoger, terwijl er ook geen effect op de globale
overleving kon worden aangetoond. Neoadjuvante CRT resul-
teert in een pathologische volledige respons (pCR) in ongeveer
20% van de patie¨nten. Indien na CRT een klinische volledige
respons wordt vastgesteld, blijft chirurgie noodzakelijk vermits
de huidig beschikbare technologie niet toelaat residuele tumor
met zekerheid uit te sluiten. De repons op CRT zal mogelijk
nog verbeteren door toevoegen van angiogenese remmers aan
de chemotherapie; daarnaast zal er mogelijk een rol zijn voor
vroege intensificatie van de chemotherapie om de overleving op
lange termijn te verbeteren.
Er zijn verschillende methoden beschreven om de tumorrespons
op RT te verbeteren terwijl de neveneffecten op de normale
weefsels beperkt blijven. In hoofdstuk vier vergeleken we
in een klinische studie neoadjuvante CRT met neoadjuvante
gehyperfractioneerde geaccelereerde radiotherapie (HART) in
de behandeling van het distaal rectumcarcinoom. De behan-
deling bestond uit 45 Gray (Gy) in 25 fracties van 1.8 Gy
met 5-FU gebaseerde chemotherapie gevolgd door TME na 6-8
weken of 41.6 Gy in 26 fracties (twee daags) van 1.6 Gy gevolgd
door onmiddellijke TME. We vonden dat CRT leidde tot meer
sphinctersparende ingrepen (74% (HART) versus 83.5% (CRT),
p=0.013). De tumorrespons was beter in de CRT group, met
214
een pCR in 4% (HART) versus 18% (CRT) van de verwijderde
specimens (p=0.002). Hoewel geen verschillen werden genoteerd
in anastomotisch lek, waren zowel vroegtijdige als late neven-
werkingen veel meer uitgesproken na HART. De ziektevrije 5
jaars overleving was 51% (HART) versus 62% (CRT), p=0.037
terwijl geen verschillen werden vastgesteld in het aantal lokale
recidieven of in de globale 5 jaars overleving.
Vroegtijdige bepaling van het antwoord op neoadjuvante ther-
apie is van groot belang voor zowel ontwikkeling van nieuwe
antitumorale behandelingen, klinische studies, en beleid bij de
individuele patie¨nt. Functionele beeldvorming laat toe, vroegti-
jdig het antwoord van het tumorvaatbed op therapie te visu-
aliseren en te quantifiren. In hoofdstuk vijf wordt dynamis-
che contrast MRI (DCE-MRI) met P792, een blood pool con-
traststof (CA) aangewend om de microvasculaire respons op RT
te bestuderen in een rat CC531 colorectaal tumormodel. De
DCE-MRI data werden verwerkt in een twee compartiment far-
macokinetisch model met genereren van parametrische kaarten
van de endotheliale transferconstante (Ktrans) en de fractie van
de extravasculaire extracellulaire ruimte (EES). De beeldvorm-
ing werd gecombineerd met meting van weefseloxygenatie en
uitgevoerd voor en vijf dagen na 5x5 Gy RT. Daarnaast wer-
den microvaat dichtheid (MVD) en expressie van de vasculaire
endotheliale groeifactor (VEGF) vergeleken met een groep niet
bestraalde tumoren. We vonden een significante reductie van
Ktrans en van de EES fractie, wijzend op een gedaalde capil-
laire permeabiliteit na RT. Hoewel de weefseloxygenatie toe-
nam na RT, bleek de expressie van VEGF hoger in bestraalde
tumoren terwijl geen significante verschillen werden genoteerd
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in MVD of expressie van de hypoxiemerker pimonidazole. In
de bestraalde tumoren kon geen correlatie worden aangetoond
tussen de DCE-MRI parameters en de MVD. Er werd een in-
verse correlatie gezien tussen pO2 and Ktrans (r = -0.57, p =
0.08) en tussen pO2 and Ve (r = -0.65, p = 0.04). Deze resul-
taten tonen aan dat DCE-MRI met een macromoleculaire CA
nuttig kan zijn in de vroegtijdige visualisatie en quantificatie
van anti-angiogenese therapie waaronder RT.
Solide tumoren vertonen onvermijdelijk een zeker mate van hy-
poxie, en het verband tussen hypoxie en zowel respons op RT
als overleving zijn aangetoond in meerdere klinische studies. Er
bestaat dan ook belangstelling in behandelingen die de tumor-
oxygenatie doen toenemen met als doel de respons op RT te ver-
beteren. In hoofdstuk zes werd het effect van exogeen toegedi-
end erythropoietine (EPO) onderzocht op de respons van tumor
microvaten op RT. Een CC531 tumor werd ge¨ınduceerd bij de
rat waarna een controlegroep en een EPO behandelde groep
5x5 Gy RT ondergingen met DCE-MRI zowel voor als 5 dagen
na de RT. De DCE-MRI data werden gefit in een meer com-
plex farmacokinetisch model dat toelaat om naast de capillaire
permeabiliteit en het bloedvolume ook de plasma flow te bereke-
nen. De beeldvorming werd gecombineerd met oxygenatiemet-
ing en immuunhistochemische bepaling van MVD, diameter,
fractale dimensie (MFD) van de microvaten (een maat voor de
geometrische complexiteit), en expressie van VEGF, hypoxie in-
duceerbare factor (HIF) 1 alpha, Bcl-2, en Bax. We vonden een
significante reductie van capillaire permeabiliteit na RT in de
controle groep, maar niet in de EPO behandelde groep. De
weefseloxygenatie was significant beter in de EPO groep, en
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RT leidde tot een ruimtelijk heterogene toename van de pO2
in beide groepen. Toediening van EPO leidde tot morfologis-
che verschillen met de controle groep na RT (grotere diameter,
lagere MFD) terwijl geen verschillen in MVD werden aangetrof-
fen. De expressie van VEGF was significant lager na RT in de
EPO behandelde groep, terwijl geen verschillen werden gevon-
den in expressie van HIF-1 alpha, Bcl-2, en Bax. Deze resultaten
suggereren een ruimtelijke modulatie van tumorale microvaten
door EPO, die waarschijnlijk zowel door rechtstreekse effecten
op het endotheel als door indirecte effecten (door gewijzigde oxy-
genatie) te verklaren zijn. De moleculaire mechanismen waar-
door EPO het antwoord van tumorale microvaten op RT wijzigt
dienen nader te worden opgehelderd.
Toekomstig werk binnen onze groep omvat onder meer molecu-
laire MR beeldvorming van de angiogenese met een CA gericht
tegen het alpha(v)beta(3) integrine. Daarnaast zal in vivo fluo-
rescentiemicroscopie worden gestart teneinde 1. over een gouden
standaard te beschikken in verband met evaluatie van capil-
laire permeabiliteitsmeting met MRI; en 2. vroege stappen van
(tumorale) angiogenese te bestuderen en het effect van anti-
angiogene behandelingen. Daarbij zal worden gebruik gemaakt
van tumorcellen die green fluorescent protein (GFP) tot ex-
pressie brengen.
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BED Biologically Equivalent Dose
BPCA Blood Pool Contrast Agent
CA Contrast Agent
cCR Clinical Complete Response
CMT Combined Modality Therapy
CRM Circumferential Resection Margin
CRT Chemoradiotherapy
CT Chemotherapy
Da Dalton
DCE-MRI Dynamic Contrast Enhanced Magnetic Resonance Imaging
EES Extravascular Extracellular Space
EPO Erythropoietin
Gd Gadolinium
Gy Gray
HART Hyperfractionated Accelerated Radiotherapy
kDa Kilodalton
Ktrans Endothelial Transfer Constant
LR Local Recurrence
MFD Microvascular Fractal Dimension
MMCA Macromolecular Contrast Agent
MRI Magnetic Resonance Imaging
MVD Microvessel Density
MW Molecular Weight
pCR Pathological Complete Response
PD Progressive Disease
PET Positron Emission Tomography
PR Partial Response
PS Permeability Surface Product
RECIST Response Criteria in Solid Tumors
rhEPO Recombinant Human Erythropoietin
RT Radiotherapy
SUV Standardised Uptake Value
TME Total Mesorectal Excision
Ve Fractional EES Volume
VEGF Vascular Endothelial Growth Factor
Vp Fractional Vascular Volume
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